Biodesix (BDSX) 10-Q 4 Aug 22 2022 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2022	Aug. 01, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Entity Central Index Key	0001439725
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	001-39659
Entity Registrant Name	BIODESIX, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-3986492
Entity Address, Address Line One	2970 Wilderness Place,
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Boulder
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80301
City Area Code	303
Local Phone Number	417-0500
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	BDSX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		39,982,048

Condensed Balance Sheets

Condensed Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 23,586	$ 32,712
Accounts receivable, net of allowance for doubtful accounts of $52 and $158	5,452	3,656
Other current assets	6,019	7,245
Total current assets	35,057	43,613
Non‑current assets
Restricted cash	5,000
Property and equipment, net	3,950	4,179
Intangible assets, net	10,688	11,617
Operating lease right-of-use assets	3,952
Goodwill	15,031	15,031
Other long-term assets	1,551	1,657
Total non‑current assets	40,172	32,484
Total assets	75,229	76,097
Current liabilities
Accounts payable	1,791	1,662
Accrued liabilities	6,667	7,665
Deferred revenue	2,230	1,850
Current portion of operating lease liabilities	1,315
Current portion of contingent consideration	8,151	17,764
Current portion of notes payable	11,771	19
Other current liabilities	1,149
Total current liabilities	33,074	28,960
Non‑current liabilities
Long‑term notes payable, net of current portion	8,596	9,993
Long-term operating lease liabilities	2,902
Contingent consideration	22,916	16,028
Other long-term liabilities	70	1,389
Total non‑current liabilities	34,484	27,410
Total liabilities	67,558	56,370
Commitments and contingencies
Stockholders' equity
Preferred stock, $0.001 par value, 5,000,000 shares authorized; 0 (2022 and 2021) shares issued and outstanding
Common stock, $0.001 par value, 200,000,000 shares authorized; 39,978,844 (2022) and 30,789,649 (2021) shares issued and outstanding	40	31
Additional paid‑in capital	341,014	321,669
Accumulated deficit	(333,383)	(301,973)
Total stockholders' equity	7,671	19,727
Total liabilities and stockholders' equity	$ 75,229	$ 76,097

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Allowance for doubtful accounts receivable	$ 52	$ 158
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized	5,000,000	5,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized	200,000,000	200,000,000
Common stock, issued	39,978,844	30,789,649
Common stock, outstanding	39,978,844	30,789,649

Condensed Statements of Operati

Condensed Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Revenues	$ 10,950	$ 11,885	$ 17,498	$ 40,751
Operating expenses:
Direct costs and expenses	3,980	7,085	7,215	25,303
Research and development	3,361	3,323	6,567	6,644
Sales, marketing, general and administrative	15,235	11,425	29,722	23,352
Change in fair value of contingent consideration		639		1,622
Impairment loss on intangible assets			81
Total operating expenses	22,576	22,472	43,585	56,921
Loss from operations	(11,626)	(10,587)	(26,087)	(16,170)
Other (expense) income:
Interest expense	(1,346)	(815)	(2,483)	(1,466)
Loss on extinguishment of liabilities	(2,952)		(2,952)	(728)
Other income, net	100		112	1
Total other expense	(4,198)	(815)	(5,323)	(2,193)
Net loss	$ (15,824)	$ (11,402)	$ (31,410)	$ (18,363)
Net loss per share, basic and diluted	$ (0.40)	$ (0.41)	$ (0.89)	$ (0.68)
Weighted-average shares outstanding, basic and diluted	39,239	27,730	35,177	27,020

Condensed Statements of Stockho

Condensed Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit
Balances at Dec. 31, 2020	$ 41,166	$ 27	$ 299,953	$ (258,814)
Common Stock Balance, Shares at Dec. 31, 2020		26,562,000
Exercise of stock options	475		475
Exercise of stock options, shares		223,000
Stock‑based compensation	1,752		1,752
Net loss	(6,961)			(6,961)
Balances at Mar. 31, 2021	36,432	$ 27	302,180	(265,775)
Common Stock Balance, Shares at Mar. 31, 2021		26,785,000
Balances at Dec. 31, 2020	41,166	$ 27	299,953	(258,814)
Common Stock Balance, Shares at Dec. 31, 2020		26,562,000
Stock‑based compensation	539
Net loss	(18,363)
Balances at Jun. 30, 2021	25,773	$ 27	302,923	(277,177)
Common Stock Balance, Shares at Jun. 30, 2021		26,949,000
Balances at Mar. 31, 2021	36,432	$ 27	302,180	(265,775)
Common Stock Balance, Shares at Mar. 31, 2021		26,785,000
Exercise of stock options	204		204
Exercise of stock options, shares		164,000
Stock‑based compensation			539
Net loss	(11,402)			(11,402)
Balances at Jun. 30, 2021	25,773	$ 27	302,923	(277,177)
Common Stock Balance, Shares at Jun. 30, 2021		26,949,000
Balances at Dec. 31, 2021	19,727	$ 31	321,669	(301,973)
Common Stock Balance, Shares at Dec. 31, 2021		30,790,000
Issuance of common stock under employee stock purchase plan	202		202
Issuance of common stock under employee stock purchase plan, Shares		99,000
Issuance of common stock for deferred offering costs	600		600
Issuance of common stock for deferred offering costs, Shares		184,000
Issuance of common stock, net	1,417	$ 1	1,416
Issuance of common stock, net, Shares		709,000
Exercise of stock options	75		75
Exercise of stock options, shares		107,000
Stock‑based compensation	1,346		1,346
Net loss	(15,586)			(15,586)
Balances at Mar. 31, 2022	7,781	$ 32	325,308	(317,559)
Common Stock Balance, Shares at Mar. 31, 2022		31,889,000
Balances at Dec. 31, 2021	$ 19,727	$ 31	321,669	(301,973)
Common Stock Balance, Shares at Dec. 31, 2021		30,790,000
Exercise of stock options, shares	130,000
Net loss	$ (31,410)
Balances at Jun. 30, 2022	7,671	$ 40	341,014	(333,383)
Common Stock Balance, Shares at Jun. 30, 2022		39,979,000
Balances at Mar. 31, 2022	7,781	$ 32	325,308	(317,559)
Common Stock Balance, Shares at Mar. 31, 2022		31,889,000
Issuance of common stock, net	14,329	$ 8	14,321
Issuance of common stock, net, Shares		7,928,000
Exercise of stock options	$ 17		17
Exercise of stock options, shares		24,000
Release of restricted stock units, shares	138,000
Stock‑based compensation	$ 1,368		1,368
Net loss	(15,824)			(15,824)
Balances at Jun. 30, 2022	$ 7,671	$ 40	$ 341,014	$ (333,383)
Common Stock Balance, Shares at Jun. 30, 2022		39,979,000

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities
Net loss	$ (31,410)	$ (18,363)
Adjustments to reconcile net loss to net cash, cash equivalents, and restricted cash used in operating activities
Depreciation and amortization	1,806	1,523
Amortization of lease right-of-use assets	728
Loss on extinguishment of liabilities	2,952	728
Stock‑based compensation expense	2,714	2,291
Change in contingent consideration		1,622
Provision for doubtful accounts	(39)	193
Accrued interest, amortization of debt issuance costs and other	2,174	502
Inventory excess and obsolescence	535
Impairment loss on intangible assets	81
Changes in operating assets and liabilities:
Accounts receivable	(1,757)	9,830
Other current assets	690	1,794
Other long-term assets	933	447
Accounts payable and other accrued liabilities	(1,195)	(9,453)
Deferred revenue	(392)	(1,350)
Current and long-term operating lease liabilities	(513)
Net cash, cash equivalents, and restricted cash used in operating activities	(22,693)	(10,236)
Cash flows from investing activities
Purchases of property and equipment	(591)	(747)
Patent costs and intangible asset acquisition, net	(141)	(117)
Net cash, cash equivalents, and restricted cash used in investing activities	(732)	(864)
Cash flows from financing activities
Proceeds from the issuance of common stock	16,135
Proceeds from issuance of common stock under employee stock purchase plan	202
Proceeds from exercise of stock options	92	679
Payment of contingent consideration	(6,625)
Proceeds from term loan and notes payable	15,102	30,078
Repayment of term loan and notes payable	(3,025)	(25,419)
Payment of debt issuance costs	(2,115)	(109)
Deferred offering costs	(129)
Equity financing costs	(323)
Other	(15)
Net cash, cash equivalents and restricted cash (used in) provided by financing activities	19,299	5,229
Net decrease in cash, cash equivalents and restricted cash	(4,126)	(5,871)
Cash, cash equivalents, and restricted cash ‑ beginning of period	32,798	62,306
Cash, cash equivalents, and restricted cash ‑ end of period	28,672	56,435
Supplemental cash flow information:
Common stock issued for deferred offering costs	600
Deferred offering costs amortized against Additional paid-in capital	18
Original issuance discount	1,025
Deferred offering costs included in Accrued liabilities	118
Equity financing costs included in Accrued liabilities	47
Operating lease right-of-use assets obtained in exchange for lease liabilities	4,672
Finance lease right-of-use assets obtained in exchange for lease liabilities	123
Cash paid for interest	$ 344	$ 720

Organization and Description of

Organization and Description of Business	6 Months Ended
	Jun. 30, 2022
Organization And Description Of Business [Abstract]
Organization and Description of Business	Note 1 – Organization and Description of Business Biodesix, Inc. (the “Company”, “Biodesix”, “we” “us” and “our”), formerly Elston Technologies, Inc., was incorporated in Delaware in 2005. The Company’s headquarters are in Colorado, with laboratories in Colorado and Kansas. The Company conducts all of its operations within a single legal entity. Biodesix is a data-driven diagnostic solutions company leveraging state of the art technologies with its proprietary artificial intelligence platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. In addition to diagnostic tests, the Company provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The Company performs its blood-based diagnostic tests in its laboratory facilities, which are located in Boulder, Colorado and De Soto, Kansas. In May 2020, the Federal Drug Administration (FDA) granted Emergency Use Authorization (EUA) of the Bio-Rad SARS-CoV-2 Droplet Digital™ polymerase chain reaction (ddPCR) test to detect Coronavirus Disease 2019 (COVID-19) infection. In April 2020, the FDA authorized the Platelia SARS-CoV-2 Total Ab test to detect COVID-19 antibodies. Medical products that are granted an EUA are only permitted to commercialize their products under the terms and conditions provided in the authorization. The FDA may revoke an EUA where it is determined that the underlying health emergency no longer exists or warrants such authorization, if the conditions for the issuance of the EUA are no longer met, or if other circumstances make revocation appropriate to protect the public health or safety. Blood-Based Lung Tests The Company offers five blood-based lung cancer tests across the lung cancer continuum of care: Diagnosis • Nodify XL2® and Nodify CDT® tests, marketed as our Nodify Lung ® Nodule Risk Assessment testing strategy, assess the risk of lung cancer to help identify the most appropriate treatment pathway. We believe we are the only company to offer two commercial blood-based tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules. Treatment & Monitoring • GeneStrat ddPCR® and VeriStrat® tests, marketed as part of our new IQLung™ testing strategy, are used following diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient’s immune system to establish the patient’s prognosis and help guide treatment decisions. The GeneStrat ddPCR tumor profiling test and the VeriStrat immune profiling test have a 36-hour average turnaround time, providing physicians with timely results to facilitate treatment decisions. • GeneStrat NGS™ (NGS) test, also marketed as part of our new IQLung testing strategy, our 72-hour average turnaround time blood-based NGS test, was launched in November 2021 to a select group of physicians, with national launch in January 2022. The 52-gene panel includes guideline recommended mutations to help physicians treating advanced-stage lung cancer patients identify targeted therapy mutations, such as EGFR, ALK, KRAS, MET, NTRK, ERBB2, and others, and delivers them in an expedited timeframe so patient treatment can begin sooner. COVID-19 Tests We operate and have commercialized the Biodesix WorkSafe testing program, under which the Company offers three SARS-CoV-2 tests: • Bio-Rad SARS-CoV-2 ddPCR test, which is FDA EUA authorized to be performed by Clinical Laboratory Institute Amendments (CLIA) authorized laboratories that perform high complexity tests. The ddPCR test is designed to detect the presence of infection by the SARS-CoV-2 virus. • Platelia SARS-CoV-2 Total Ab test, which is an antibody test, FDA EUA authorized, intended for detecting a B-cell immune response to SARS-CoV-2, indicating recent or prior infection. • cPass™ SARS-CoV-2 Neutralization Antibody test , which is the first blood-based surrogate neutralizing antibody test with FDA EUA and uses ELISA technology to qualitatively detect circulating neutralizing antibodies to the receptor binding domain (RBD) in the spike protein of SARS-CoV-2 that are produced in response to a previous SARS-CoV-2 infection. This test was commercially introduced in partnership with GenScript Biotech Corporation. These tests under the Biodesix WorkSafe testing program are utilized by healthcare providers, including hospitals and nursing homes, and are also offered to businesses and educational systems to assist in their back-to-work or back-to-school strategies, a crucial element of restarting economic activity. In developing the Company's products, the Company has built or gained access to unique biorepositories, proprietary technology, and bioinformatics methods that it believes are important to the development of new targeted therapies, determining clinical trial eligibility and guiding treatment selection. The Company’s testing services are made available through its clinical laboratories.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X for interim financial information and reflect all adjustments necessary to state fairly the Company’s financial position, results of operations and cash flows for the interim periods presented. All such adjustments are of a normal recurring nature. Results for interim periods are not indicative of the results for the entire fiscal year. The accompanying Condensed Financial Statements should be read in conjunction with the audited Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. Certain information and footnote disclosures, including significant accounting policies, normally included in fiscal year financial statements prepared in accordance with accounting principles generally accepted in the U.S. (GAAP) have been condensed or omitted. The Condensed Balance Sheet as of December 31, 2021 was derived from the audited financial statements. As of June 30, 2022, we maintained cash and cash equivalents of $ 28.7 million, inclusive of $ 5.1 million in restricted cash (see Restricted Cash below), and we have $ 23.2 million in outstanding aggregate principal amount on our 2021 Term Loan and Promissory Note One. We have incurred significant losses since inception and, as a result, we have funded our operations to date primarily through the sale of common stock, the sale of convertible preferred stock, the issuance of notes payable, and from our two primary revenue sources: (i) diagnostic testing, which include lung diagnostic testing and COVID-19 testing, and (ii) providing biopharmaceutical companies with development and testing services. In accordance with Accounting Standards Update 2014-15 (ASC Topic 205-40), Presentation of Financial Statements - Going Concern: Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern , the Company is required to evaluate whether there is substantial doubt about its ability to continue as a going concern each reporting period, including interim periods. In evaluating the Company’s ability to continue as a going concern, management projected its cash flow sources, including the debt and equity funding and amendments to the 2021 Term Loan and Integrated Diagnostics, Inc. (Indi) Agreement, and evaluated the conditions and events that could raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these financial statements were issued. Management considered the Company’s current projections of future cash flows, current financial condition, sources of liquidity and debt obligations for at least one year from the date of issuance of this Form 10-Q in considering whether it has the ability to meet its obligations. Our ability to meet our obligations as they come due may be impacted by our ability to remain compliant with financial covenants in our loan agreements (see Note 6 – Debt ) or to obtain waivers or amendments that impact the related covenants. Due to the continued uncertainty caused by the COVID-19 pandemic, significant risks remain with respect to our ability to meet these thresholds and any material adverse effect on our revenues, income and expenses could impact our ability to maintain compliance with these covenants. Based on our current operating plan, unless we continue to raise additional capital (debt or equity) or obtain a waiver from complying with such financial covenants, we expect that we will be unable to maintain our financial covenants under our existing loan agreements during the next twelve months, which could result in an Event of Default, as defined, causing an acceleration and repayment of the outstanding balances. We have taken steps to improve our liquidity through raising debt and equity capital during 2022, amendments to our 2021 Term Loan, and have also undertaken several proactive measures to mitigate the financial and operational impacts of the COVID-19 pandemic through the reduction of planned capital expenditures and certain operating expenses but we do not expect that these actions alone will be sufficient to maintain our financial covenants. During the three months ended June 30, 2022, we entered into a $ 25.0 million debt facility with funding for up to $ 25.0 million in two tranches. On May 9, 2022, we closed on the first tranche for gross proceeds of $ 15.0 million (approximately $ 12.8 million, net, after deducting debt issuance costs and original issue discounts (OID)). We also amended the Indi Agreement to delay near term cash requirements and extend the period of milestone payments. To maintain an adequate amount of available liquidity and execute our current operating plan, we will need to continue to raise additional funds from external sources, such as through the issuance of equity or debt securities; however, we have not secured such funding at the time of this filing and any such financing activities are subject to market conditions. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our existing stockholders’ rights. There can be no assurance that additional capital will be available to us or, if available, will be available in sufficient amounts or on terms acceptable to us or on a timely basis. If adequate capital resources are not available on a timely basis, we intend to consider limiting our operations substantially. This limitation of operations could include a hiring freeze, reductions in our workforce, reduction in cash compensation, deferring capital expenditures, and reducing other operating costs. The Company’s revenues, results of operations and cash flows have been materially adversely impacted by the items noted above. Our current operating plan, which is in part determined based on our most recent historical actual results and trends, along with the items noted above, raises substantial doubt about the Company’s ability to continue as a going concern. Our unaudited financial statements have been prepared assuming we will continue as a going concern and do not include any adjustments that might be necessary should we be unable to continue as a going concern. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the balance sheet date and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates. Restricted Cash Restricted cash consists of the $ 5.0 million cash collateralized letter of credit for the benefit of the landlord (lessor) to secure the performance of the Company’s obligations under an operating lease agreement with Centennial Valley Properties I, LLC (see Note 7 – Leases ). In addition, $ 0.1 million of deposits related to the Company’s corporate credit cards are reported within ‘Other current assets’ in the balance sheets as of June 30, 2022 and December 31, 2021, respectively . Concentration of Credit Risk and Other Uncertainties Substantially all of the Company’s cash and cash equivalents are deposited with two major financial institutions in the United States. The Company continually monitors its positions with, and the credit quality of, the financial institution with which it holds cash. Periodically throughout the year, the Company has maintained balances in various operating accounts in excess of federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents. Several of the components for certain of the Company's sample collection kits, test reagents, and test systems are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company's requirements on a timely basis, it could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results. For a discussion of credit risk concentration of accounts receivable as of June 30, 2022 and December 31, 2021, see Note 9 – Revenue and Accounts Receivable Credit Concentration . Inventory Inventory consists primarily of material supplies, which are consumed in the performance of testing services and charged to ‘Direct costs and expenses’. Inventory is stated at cost and reported within ‘Other current assets’ in the balance sheet and was $ 1.9 million an d $ 2.9 million as of June 30, 2022 and December 31, 2021 , respectively. Fair Value of Financial Instruments U.S. GAAP for fair value establishes a hierarchy that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques (market approach, income approach, and cost approach). We utilize a combination of market and income approaches to value our financial instruments. Our financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. Fair value measurements are categorized within the fair value hierarchy based upon the lowest level of the most significant inputs used to determine fair value. The three levels of the hierarchy and the related inputs are as follows: Level Inputs 1 Unadjusted quoted prices in active markets for identical assets and liabilities. 2 Unadjusted quoted prices in active markets for similar assets and liabilities; Unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or Inputs other than quoted prices that are observable for the asset or liability. 3 Unobservable inputs for the asset or liability. The carrying amounts of certain financial instruments including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities. See Note 4 — Fair Value for further discussion related to estimated fair value measurements.

Recently Issued Accounting Stan

Recently Issued Accounting Standards	6 Months Ended
	Jun. 30, 2022
Accounting Standards Update and Change in Accounting Principle [Abstract]
Recently Issued Accounting Standards	Note 3 - Recently Issued Accounting Standards Recently adopted accounting standards In February 2016, the FASB issued Account Standard Update (ASU) No. 2016-2, Leases (ASC 842). This ASU intends to make accounting for leasing activities more transparent and comparable, and requires substantially all leases be recognized by lessees on their balance sheet as a right-of-use asset and corresponding lease liability, including leases accounted for as operating leases. In addition to other related amendments, the FASB issued ASU No. 2018-11, Leases (Topic 842): Targeted Improvements, which offers an additional transition method whereby entities may apply the new leases standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings rather than application of the new leases standard at the beginning of the earliest period presented in the financial statements. T he Company elected this transition method and adopted ASC 842 on January 1, 2022 and as a result, recorded operating lease right-of-use (ROU) assets of $ 1.3 million, including offsetting deferred rent of $ 0.1 million, along with the associated operating lease liabilities of $ 1.3 million. On January 1, 2022, the Company did not have any finance leases. The adoption of ASC 842 did not result in a cumulative effect adjustment to beginning retained earnings, and did not materially affect the Company's statement of operations, statement of stockholders' equity or statement of cash flows for the six months ended June 30, 2022. In addition, the Company elected the following practical expedients permitted under the transition guidance within the new standard: • Package of practical expedients which allows the Company to carry forward the historical lease classification; • Hindsight practical expedient which allows the Company to use hindsight in determining the lease term, in assessing purchase options, and in assessing impairment of ROU assets; • Short-term lease practical expedient which allows the Company to capitalize only those leases with an initial term of twelve months or more, and; • The practical expedient to account for lease and non-lease components (such as common area maintenance, utilities, insurance and taxes) as a single lease component for all classes of underlying assets. Management determines if an arrangement is a lease at inception or upon modification of a contract. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the statements of operations. When determining whether a lease is a finance lease or an operating lease, ASC 842 does not specifically define criteria to determine the “major part of remaining economic life of the underlying asset” and “substantially all of the fair value of the underlying asset.” For lease classification determination, Management continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset. ROU assets represent the Company's right to use an underlying asset for the lease term. Lease liabilities represent the Company's obligation to make lease payments under the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, the Company uses either the rate implicit in the lease or its incremental borrowing rate, as applicable, based on the information available at lease commencement date. The Company applies the estimated incremental borrowing rates on a lease-by-lease level based on the economic environment associated with the lease. The operating lease ROU asset also includes any lease prepayments, net of lease incentives. Certain of the Company's leases include options to extend or terminate the lease. As leases approach maturity, the Company considers various factors such as market conditions and the terms of any renewal and termination options that may exist to determine whether we will renew or terminate the lease, as such, we generally do not include renewal or termination options in our lease terms for calculating our lease liability, as the options allow us to maintain operational flexibility and we are not reasonably certain we will exercise these options at the time of the lease commencement. The Company's lease agreements do not contain any material residual value guarantees or restrictive covenants. Lease expense for lease payments of operating leases is recognized on a straight-line basis over the term of the lease. The Company uses the long-lived assets impairment guidance to determine recognition and measurement of an ROU asset impairment, if any. The Company monitors for events or changes in circumstances that require a reassessment. Additional information and disclosures required by this new standard are contained in Note 7 — Leases . Standards Being Evaluated In June 2016, the FASB issued ASU No. 2016-13 , Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments (ASC Topic 326). This ASU requires measurement and recognition of expected credit losses for financial assets. This guidance will become effective for the Company beginning January 1, 2023 with early adoption permitted. The Company is currently evaluating this guidance and assessing the overall impact on its financial statements.

Fair Value

Fair Value	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value	Note 4 - Fair Value Recurring Fair Value Measurements Our borrowing instruments are recorded at their carrying values in the balance sheets, which may differ from their respective fair values. The difference between the carrying value and fair value of outstanding borrowings as of June 30, 2022 is due to the debt issuance costs and OID netted against Promissory Note One entered into with Streeterville Capital, LLC, in May 2022. The carrying value of outstanding borrowings as of December 31, 2021, approximates fair value based on interest rates available at that time for similar borrowings. The table below presents the carrying and fair values of outstanding borrowings, which are classified as Level 2, as of the dates indicated (in thousands): As of June 30, 2022 December 31, 2021 Carrying Value Fair Value Carrying Value Fair Value Borrowings $ 20,367 $ 23,317 $ 10,012 $ 10,012 The financial liabilities that are measured and recorded at estimated fair value on a recurring basis consist of our contingent consideration associated with our previous acquisition of Indi which is accounted for as a liability and remeasured through our statements of operations. The table below presents the reported fair values of contingent consideration, which is classified as Level 3 in the fair value hierarchy, as of the dates indicated (in thousands): Description June 30, 2022 December 31, 2021 Current portion of contingent consideration $ 8,151 $ 17,764 Contingent consideration 22,916 16,028 Total contingent consideration $ 31,067 $ 33,792 The following table presents the changes in contingent consideration for the six months ended June 30, 2022 and 2021 (in thousands): For the six months Level 3 Rollforward 2022 2021 Beginning balances - January 1 $ 33,792 $ 29,932 Changes in fair value — 1,622 Interest expense 966 289 Loss on extinguishment of liabilities 2,934 — Payments of contingent consideration ( 6,625 ) — Ending balances - June 30 $ 31,067 $ 31,843 Contingent Consideration In connection with the acquisition of Indi in 2018, the Company recorded contingent consideration for amounts contingently payable to Indi's selling shareholders pursuant to the terms of the asset purchase agreement (the Indi APA). The contingent consideration arrangement requires additional consideration to be paid by the Company to such shareholders upon attainment of a three-consecutive month gross margin target of $ 2.0 million within the seven-year period after the acquisition date. Under the terms of the original agreement, when the gross margin target was met the Company was required to issue 2,520,108 shares of common stock. For the six months following the achievement of the gross margin target, Indi had the option to require the Company to redeem these common shares for $ 37.0 million in cash over eight equal quarterly installments. If Indi elected to not exercise its option, the Company had 12 months to repurchase the common stock in two equal and consecutive quarterly cash installments totaling $ 37.0 million. The Company met the gross margin target of $ 2.0 million for three consecutive months during the three months ended June 30, 2021. The Company entered into an amendment to the original agreement in August 2021 in which all parties agreed to forgo the issuance of common stock and agreed that the Company will in lieu thereof make six quarterly installments of approximately $ 4.6 million each beginning in January 2022 and a final payment of approximately $ 9.3 million in July 2023 for a total of $ 37.0 million. The aggregate amount of payments owed by the Company under this amendment is the same as if Indi had exercised the put right or the Company had exercised the call right provided for in the original agreement. On April 7, 2022, the Company entered into Amendment No. 3 to the Indi APA in which the parties agreed to restructure the milestone payments whereby the Company will make five quarterly installments of $ 2.0 million each beginning in April 2022, three quarterly installments of $ 3.0 million beginning in July 2023, one installment of $ 5.0 million in April 2024, and one installment of approximately $ 8.4 million in July 2024. In addition, the Company agreed to an exit fee of approximately $ 6.1 million in October 2024. Interest shall accrue on the difference between the payment schedule as agreed in the August 2021 amendment and the April 2022 amended payment schedule, at an aggregate per annum rate equal to 10 %, with such interest to be payable quarterly on the following installment payment date. Our ability to make these payments are subject to consent from our lender under the 2021 Term Loan and related amendments (see Note 6 - Debt ). We have obtained lender consent for contractual payments through the third milestone and interest payment of $ 2.1 million paid in July 2022. The contingent consideration liability is accounted for at fair value and subject to certain unobservable inputs. The significant unobservable inputs used in the measurement of the fair value include the probability of successful achievement of the specified product gross margin targets, the period in which the targets were expected to be achieved, and discount rates which ranged fro m 11 % to 16 %. A s a result of the achievement of the gross margin target, the only remaining significant unobservable input used in the measurement of fair value includes the discount rate since all other inputs became fixed and determinable. Significant increases or decreases in the discount rate would result in a significantly higher or lower fair value measurement. During the three months ended June 30, 2022, the Company recorded $ 1.1 million in interest expense due to the passage of time and fixed payment schedule, partially offset by a reduction to the contingent consideration balance of $ 1.0 million due to an increase in the discount rate to reflect current market and Company specific conditions, resulting in $ 0.1 million, ne t recorded as ‘Interest expense’ in the statements of operations. The Company evaluated Amendment No. 3 to the Indi APA in accordance with applicable accounting standards under U.S. GAAP which resulted in the extinguishment of the original instrument due to the substantially different terms. As a result, during the three months ended June 30, 2022, we recorded a loss on extinguishment of $ 2.9 million in the statements of operations. Contingent consideration expected to be paid in the next twelve months is recorded in the balance sheets as ‘Current portion of contingent consideration’ while the remaining amount to be paid is recorded as ‘Contingent consideration’ within non-current liabilities. The net change to contingent consideration through the date the gross margin target was met is recorded as operating expenses in the statements of operations. Subsequent changes to the contingent consideration following the achievement of the gross margin target are recorded as ‘Interest expense’ in the statements of operations resulting from the passage of time and fixed payment schedule. Non-Financial Assets and Liabilities Our non-financial assets, which primarily consist of property and equipment, goodwill, and other intangible assets, are not required to be carried at fair value on a recurring basis and are reported at carrying value. There were no changes to the valuation methods during the periods presented.

Supplementary Balance Sheet Inf

Supplementary Balance Sheet Information	6 Months Ended
	Jun. 30, 2022
Balance Sheet Related Disclosures [Abstract]
Supplementary Balance Sheet Information	Note 5 – Supplementary Balance Sheet Information Property and equipment consist of the following (in thousands): June 30, 2022 December 31, 2021 Lab equipment $ 6,725 $ 6,784 Leasehold improvements 2,365 2,339 Computer equipment 703 700 Furniture and fixtures 341 391 Software 325 600 Vehicles 97 97 Construction in process 411 17 10,967 10,928 Less: accumulated depreciation ( 7,017 ) ( 6,749 ) Total property and equipment, net $ 3,950 $ 4,179 Depreciation expense for the three and six months ended June 30, 2022 was $ 0.4 million and $ 0.8 million, respectively, compared to $ 0.2 million and $ 0.5 million for the three and six months ended June 30, 2021, respectively. Intangible assets, excluding goodwill, consist of the following (in thousands): June 30, 2022 December 31, 2021 Cost Accumulated Net Carrying Value Cost Accumulated Net Carrying Value Intangible assets subject to amortization Patents $ 1,785 $ ( 599 ) $ 1,186 $ 1,755 $ ( 566 ) $ 1,189 Purchased technology 16,900 ( 7,512 ) 9,388 16,900 ( 6,572 ) 10,328 Intangible assets not subject to Trademarks 114 — 114 100 — 100 Total $ 18,799 $ ( 8,111 ) $ 10,688 $ 18,755 $ ( 7,138 ) $ 11,617 Amortization expense related to definite-lived intangible assets w as $ 0.5 million and $ 1.0 million for both the three and six months ended June 30, 2022 and 2021, respectively. Future estimated amortization expense of intangible assets is (in thousands): As of June 30, 2022 Remainder of 2022 $ 986 2023 1,970 2024 1,960 2025 1,954 2026 1,941 2027 and thereafter 1,763 Total $ 10,574 Accrued liabilities consist of the following (in thousands): June 30, 2022 December 31, 2021 Compensation related accruals $ 3,570 $ 4,029 Accrued clinical trial expense 908 870 Other expenses 2,189 2,766 Total accrued liabilities $ 6,667 $ 7,665

Debt

Debt	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Debt	Note 6 – Debt Our long-term debt primarily consists of notes payable associated with Promissory Note One and our 2021 Term Loan which is described in further detail below. Long-term notes payable were as follows (in thousands): June 30, 2022 December 31, 2021 Promissory Note One $ 16,164 $ — 2021 Term Loan 7,000 10,000 Other 153 75 Unamortized debt discount and issuance costs ( 2,950 ) ( 63 ) 20,367 10,012 Less: current maturities 11,771 19 Long-term notes payable $ 8,596 $ 9,993 Securities Purchase Agreement On May 9, 2022 ( the First Closing Date), the Company entered into a securities purchase agreement (the SPA) with Streeterville Capital, LLC (Lender), pursuant to which, among other things, the Lender: (i) purchased a secured promissory note (Promissory Note One) in the aggregate principal amount totaling $ 16.0 million in exchange for $ 15.0 million less certain expenses and (ii) agreed to purchase another secured promissory note at the Company’s election (Promissory Note Two and, together with Promissory Note One, the Promissory Notes), subject to certain conditions precedent in aggregate principal amount totaling $ 10.3 million in exchange for $ 10.0 million in cash proceeds. Each of the Promissory Notes may, at the Company's option, be settled in shares of common stock of the Company (the Common Stock), upon the terms and subject to the limitations and conditi ons set forth in the Promissory Notes. The Company's net proceeds from the issuance of Promissory Note One were approximately $ 12.8 million, after deducting debt issuance costs and original issue discount ( OID). The Company intends to use the proceeds from such issuance for general corporate purposes. The Promissory Notes have a stated interest rate of 6 % per annum. The maturity date of each Promissory Note is 24 months from the issuance date of such Note (the Maturity Date). Promissory Note One was issued with an OID of $ 1.0 million while Promissory Note Two, if issued, will be subject to an OID of $ 0.3 million subject to certain contingencies which could increase the OID by an additional $ 0.5 million. The Promissory Notes are eligible for early payment for cash, at the Company’s election, subject to a prepayment premium of 10 % of the outstanding principal balance. The Company’s ability to draw Promissory Note Two is subject to the satisfaction, among other things, of the following conditions : (i) within nine months following the First Closing Date, repayment in full all outstanding obligations under the 2021 Term Loan, (ii) the Com pany shall have received no less than $ 5.6 million in proceeds from the sale (not attributable to Lender or its affiliates) of newly issued equity securities during the period beginning on the First Closing Date and ending on January 31, 2023 (the Second Closing Date), (iii) on or before the Second Closing Date, the Company shall have met or exceeded Revenue Milestone 1 (as defined in the Promissory Notes), (iv) (a) the aggregate market value of the Company’s common stock and any other equity securities held by persons that are not affiliates of the Company on the Second Closing Date sh all be greater than or equal to $ 75.0 million or (b) received no less than $ 20.0 million in additional proceeds from the sale (not attributable to Lender or its affiliates) of new equity securities in the Company not counting those proceeds set forth in item (ii) above (for total proceeds o f no less than $ 25.6 million during the period begi nning on the First Closing Date and ending on the Second Closing Date; (v) as of the Second Closing Date, Company is in good standing with Nasdaq Stock Market (the NASDAQ) and has not received any notice of non-compliance; (vi) Company shall be current in its payments to Indi, and (vii) there being no Trigger Event (as defined in the Promissory Notes) under Promissory Note One. If Promissory Note Two is issued, the terms of Promissory Note One and Note Two will be substantively identical. Under the SPA, the parties provided customary representations and warranties to each other. Also, until all amounts due under the Promissory Notes are paid in full, the Company agreed, among other things, to: (i) timely make all filings under the Securities Exchange Act of 1934, (ii) ensure that its Common Stock continues to be listed on the NASDAQ or the New York Stock Exchange, (iii) not enter into any agreement or otherwise agree to any covenant, condition, or obligation that locks up, restricts in any way or otherwise prohibits Company: (a) from entering into a variable rate transaction with Lender or any affiliate of Lender, or (b) from issuing Common Stock, preferred stock, warrants, convertible notes, other debt securities, or any other Company securities to Lender or any affiliate of Lender, (iv) will not make any Restricted Issuances (as defined in the Promissory Notes) without Lender ’s prior written consent, which consent may be granted or withheld in Lender’s sole and absolute discretion (v) within 9 months following the First Closing Date, the Company will repay in full all outstanding obligations under the 2021 Term Loan, (vi) beginning on April 1, 2023, Company shall maintain a minimum liquidity balance of at least $ 3.0 million (which liquidity balance shall only include cash, cash equivalents and accounts receivable), and (vii) offer the Lender the right to purchase up to 30 % of future equity and debt securities offerings, subject to certain exceptions and limitations. The Company also agreed under the SPA to reserve with the Company’s transfer agent 37.0 million shares of Common Stock for potential issuance under the Promissory Notes for shares that may be delivered in connection with the redemption right, which reservation may be increased and decreased in certain circumstances. Beginning on the date that is nine months after the issuance date of the applicable Promissory Note, the Lender has the right to redeem up to $ 1.4 million and $ 1.0 million of the outstanding balance of Promissory Note One and Promissory Note Two per month, respectively. Payments may be made by the Company, at the Company’s option, either in (a) in cash, or (b) in the form of shares of Common Stock with the number of redemption shares being equal to the portion of the applicable redemption amount divided by the Redemption Conversion Price or (c) a combination of cash and shares of Common Stock. The Promissory Notes have a 6 % exit fee on any redemption amount paid in cash. The Redemption Conversion Price shall equal 85% multiplied by the lowest daily VWAP during the ten trading days immediately preceding the date the Lender delivers notice electing to redeem a portion of the Promissory Note. The Company’s right to satisfy the redemption amount in shares of Common Stock is subject to certain limitations, including (i) there not being any Equity Conditions Failure (as defined in the Note), (ii) the Lender and its affiliates together not owning more than 9.99% of the outstanding shares of Common Stock, and (iii) the aggregate shares of Common Stock issued upon redemption of the Promissory Notes not exceeding 19.99% of the outstanding Common Stock unless the Company has obtained stockholder approval under NASDAQ rules for such issuance. The Promissory Notes contain certain Trigger Events that generally, if uncured within five trading days, may result in an event of default in accordance with the terms of the Promissory Notes (such event, an Event of Default). Upon an Event of Default, the interest rate may also be increased to the lesser of 15 % per annum or the maximum rate permitted under applicable law. The Company evaluated Promissory Note One in accordance with applicable accounting standards under U.S. GAAP and determined the classification of the instrument as a debt obligation. In addition, the Company evaluated the instrument for embedded derivatives and concluded there were no embedded features that require bifurcation and separate accounting. The Company will record interest expense over the term of Promissory Note One, using the interest method, to amortize the debt issuance costs and OID. On May 9, 2022, the Company recorded OID and debt issuance costs of $ 3.2 million as a reduction to Promissory Note One to be amortized over the term of Promissory Note One. For the period from May 9, 2022 to June 30, 2022, the Company recorded $ 0.3 million for amortization of the OID and debt issuance costs to interest expense in the accompanying statements of operations. For the period from May 9, 2022 to June 30, 2022, the Company recorded interes t expense of $ 0.1 million in the accompanying statements of operations and as of June 30, 2022, recorded $ 0.1 million in acc rued interest in 'Current portion of notes payable' in the accompanying balance sheets. 2021 Term Loan On March 19, 2021 (Effective Date), the Company entered into a Loan and Security Agreement (the 2021 Term Loan) by and between Silicon Valley Bank, a California corporation (SVB or Lender) and the Company, as borrower, whereby subject to the terms and conditions of the 2021 Term Loan, SVB advanced to the Company an original principal amount of $ 30 million. The 2021 Term Loan provides for an “interest-only” period from the Effective Date through February 28, 2023, with interest due and payable monthly on the first calendar day of each month. However, the Company achieved a revenue milestone of at least $ 65 million on a trailing twelve-month basis during the three months ended March 31, 2021 which automatically extended the interest-only period through February 28, 2024. Beginning on the first calendar day of the month following the end of the interest-only period, the 2021 Term Loan shall be payable in (i) consecutive equal installments of principal through March 1, 2026, plus (ii) monthly payments of accrued interest. The principal amount outstanding under the 2021 Term Loan shall accrue interest at a floating per annum rate equal to the greater of (i) 2.00% above the prime rate, or (ii) 5.25%, which interest, in each case, shall be payable monthly. Changes to the interest rate applicable to the 2021 Term Loan based on changes to the prime rate shall be effective on the effective date of any change to the prime rate. The Company has the option to prepay, prior to maturity, the total outstanding principal amount plus accrued and unpaid interest, subject to a prepayment penalty of 3 % of the principal amount if paid prior to the first anniversary of the Effective Date, 2 % of the principal amount if paid on or after the first anniversary but prior to the second anniversary of the Effective Date, 1 % of the principal amount if paid on or after the second anniversary but prior to October 19, 2025, and 0 % thereafter. The Company granted the Lender a security interest in substantially all of the Company’s assets. The 2021 Term Loan requires the Company to comply with a minimum liquidity ratio covenant (as defined) by the 2021 Term Loan of not less than 0.95 to 1.00, and had a trailing six month rolling minimum revenue requirement of not less than 70 % of the Company’s projected revenue performed at the end of each reporting period. On September 30, 2021, we entered into the Consent and First Amendment to Loan and Security Agreement (the 2021 Term Loan Amendment) to, among other things, amend our 2021 Term Loan to eliminate the revenue covenant for the period ended September 30, 2021 and modify the revenue covenant threshold for the three months ended December 31, 2021. In addition, we agreed to establish a restricted cash collateral account for $ 15 million for the benefit of our lender if the balance of our cash and cash equivalents declined below $ 40 million. On December 31, 2021, we entered into the Consent and Second Amendment to Loan and Security Agreement (the 2021 Term Loan Second Amendment) to, among other things, amend our 2021 Term Loan and First Amendment to: (i) obtain consent for the $ 4.6 million January 2022 milestone payment under the Indi APA, (ii) repay $ 20 million in outstanding principal on December 31, 2021, (iii) waive the $ 600,000 prepayment fee on the $ 20 million Term Loan repayment, (iv) waive the minimum revenue covenant as of December 31, 2021, and (v) modify the minimum revenue requirement to not less than 75 % for the three months ended March 31, 2022 and not less than 75 % on a trailing six month rolling basis for each quarter thereafter of the Company’s projected revenue performed at the end of each reporting period. The Lender agreed to apply the full amount of funds previously established within the restricted cash collateral account to partially repay the $ 20 million in outstanding principal, thereby eliminating the restricted cash collateral account. On April 7, 2022, the Company entered into the Consent and Third Amendment to Loan and Security Agreement (the 2021 Term Loan Third Amendment). Under the terms of the 2021 Term Loan Third Amendment, the Company agreed to the repayment of $ 3.0 million in outstanding principal in April 2022 with an additional $ 2.0 million to be paid on September 30, 2022, in exchange for: (i) consent for a $ 2.0 million April 2022 milestone payment under the Indi APA, as amended, (ii) waiver of minimum revenue requirement for the three months ended March 31, 2022 and adjustment of remaining revenue milestones for 2022, and (iii) waiver and elimination of the prepayment fee on the $ 3.0 million 2021 Term Loan partial repayment in April 2022 and subsequent $ 2.0 million principal repayment. The Company recorded a loss on extinguishment of $ 18 ,000 resulting from the write-off of debt issuance costs associated with the $ 3.0 million repayment of our 2021 Term Loan in April 2022. In association with entering into the SPA with the Lender on May 9, 2022 (as described above), the Company has the election to issue Promissory Note Two subject to the Company satisfying, among other things, repaying in full all outstanding obligations under the 2021 Term Loan within nine months following the First Closing Date. As of June 30, 2022, the Company intends to repay all outstanding obligations under the 2021 Term Loan within nine months of the inception of Promissory Note One. The Company’s final payment to SVB shall include all outstanding principal and accrued and unpaid interest, lender fees and expenses, which will include a final payment of $ 2.7 million, and all other sums, if any, that shall have become due and payable hereunder with respect to the 2021 Term Loan. The $ 2.7 million final payment is being amortized as interest expense over the expected remaining term of the loan. The 2021 Term Loan contains certain covenants limiting the ability of the Company to, among other things, incur future debt, transfer assets except for the ordinary course of business, make acquisitions, pay dividends or make other certain restricted payments, or sell assets, subject to certain exceptions, without the prior written consent of the Lender. Failure to comply with the covenants and loan requirements may result in an event of default. As of June 30, 2022, the Company was in compliance with all restrictive and financial covenants associated with its borrowings. In the event of a default, including, among other things, our failure to make any payment when due or our failure to comply with any covenant under the 2021 Term Loan, the Lender may elect to declare all amounts outstanding to be immediately due and payable, and may proceed against the collateral granted to them to secure such indebtedness, including a royalty-free license or other right to use all of our intellectual property without charge. Scheduled principal repayments (maturities) of long-term obligations were as follows (in thousands): As of June 30, 2022 Remainder of 2022 $ 7,023 2023 14,616 2024 1,647 2025 25 2026 6 2027 and thereafter — Total $ 23,317

Leases

Leases	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Leases	Note 7 - Leases Operating Leases The Company acts as a lessee under all its lease agreements. The Company leases its headquarters and laboratory facilities in Boulder, Colorado, under a non-cancelable lease agreement for approximately 29,722 square feet that was set to expire in January 2023 . In January 2022, the Company amended the agreement to extend the lease agreement through January 2024 , resulting in an additional $ 1.2 million in ROU as sets and lease liabilities recorded during the three months ended March 31, 2022. The Company also leases laboratory and office space in De Soto, Kansas, under a non-cancelable lease agreement for approximately 9,066 square feet that expires in October 2023 . The Company also holds various copier and storage facility leases under non-cancelable lease agreements that expire in the next one to four years . Centennial Valley Properties I, LLC Lease Agreement On March 11, 2022, the Company entered into a Lease Agreement (the Lease) with Centennial Valley Properties I, LLC, a Colorado limited liability company (the Landlord) for office and laboratory space located at 919 West Dillion Road; Louisville, Colorado (the Leased Premises). The purpose of the Lease is to replace the Company’s current leased premises at 2970 Wilderness Place, Suite 100 in Boulder, Colorado and the Company intends to move its corporate headquarters to the Leased Premises by mid-2023. The initial term of the Lease is twelve years (the Initial Term) from the commencement date, which is the earlier of: (i) the Company conducting revenue generating business (as defined in the Lease), or (ii) April 1, 2023 (the Commencement Date), unless earlier terminated in accordance with the Lease. The Company has two renewal options to extend the term of the Lease for an additional seven or ten year terms for each renewal. D uring the three months ended June 30, 2022, the lease commenced for accounting purposes resultin g in $ 2.0 million in ROU as sets and lease liabilities being recorded. Under the Lease, the Company will lease approximately 79,980 square feet at the Leased Premises. The Company will pay base rent over the life of the Lease beginning at approximately $ 227,000 per month and escalating, based on fixed escalation provisions, to approximately $ 326,000 per month, plus certain operating expenses and taxes. The Company's obligation to pay base rent shall be abated, commencing as of the Commencement Date and ending on and including the date that is 12 months after the Commencement Date (the Abated Rent Period). Further, the Company's obligation to pay base rent with respect to a portion of the area of the Lease Premises equal to 19,980 square feet shall be abated (the Partial Abated Rent), commencing as of the day after the end of the Abated Rent Period and ending on and including the date that is 24 months after the Commencement Date (the Partial Abated Rent Period). Pursuant to a work letter entered by the parties in connection with the Lease, the Landlord will contribute an aggregate of $ 18.8 million toward the cost of construction and improvements for the Leased Premises and the Company exercised its option for an additional tenant improvement allowance of $ 2.0 million (the Extra Allowance Amount). The Company will repay the Extra Allowance Amount actually funded by the Landlord in equal monthly payments with an interest rate of 6 % per year over the Initial Term excluding any part of the Abated Rent Period or Partial Abated Rent Period, which shall start to accrue on the date that the Landlord first disburses the Extra Allowance Amount. The Company made an accounting policy election to reduce the right-of-use asset and lease liability because the Lease specifies a maximum level of reimbursement for tenant improvements which are probable of being incurred and within the Company's control. Due to the tenant improvement allowances at the accounting lease co mmencement date and rent abatement periods described above, the Company expects the lease liability to accrete to approximately $ 25.7 million by March 2024. The Lease includes various covenants, indemnities, defaults, termination rights, and other provisions customary for lease transactions of this nature, including maintaining a $ 5.0 million letter of credit (subject to contingent reduction over the term of the lease) to secure the performance of the Company’s obligations under the Lease. The $ 5.0 million letter of credit has to be cash collateralized by the Company through a restricted cash account for the benefit of the Landlord, which we recognized contemporaneously with the commencement of the Lease for accounting purposes. Operating lease expense w as $ 0.5 million and $ 0.8 million for the three and six months ended June 30, 2022 , respectively, compared to $ 0.3 million and $ 0.6 million for the three and six months ended June 30, 2021, respectively. As of June 30, 2022 , the weighted-average remaining lease term and discount rate associated with our operating leases were 7. 0 years and 11.40 %, respectivel y. Future minimum lease payments associated with our operating leases were as follows (in thousands): As of June 30, 2022 Remainder of 2022 (1) $ ( 9,732 ) 2023 (1) ( 8,121 ) 2024 2,619 2025 3,710 2026 3,979 2027 and thereafter 36,327 Total future minimum lease payments 28,782 Less amount representing interest ( 24,565 ) Total lease liabilities $ 4,217 (1) Includes $ 20.8 million of tenant improvement allowances expected to be received during these periods. Future minimum lease payments, which do not include amounts for common area maintenance, insurance, or taxes, for operating lease obligations in accordance with ASC 840 - Leases were as follows (in thousands): As of December 31, 2021 2022 $ 775 2023 149 2024 9 2025 3 2026 1 2027 and thereafter — Total $ 937

Equity

Equity	6 Months Ended
	Jun. 30, 2022
Stockholders' Equity Note [Abstract]
Equity	Note 8 – Equity Equity Financing Programs The Company maintains two facilities that enable equity financing on an ongoing basis at the Company’s sole discretion, our at-the-market offering and our common stock purchase agreement with Lincoln Park Capital Fund, LLC (the LPC facility). In November 2021, the Company entered into a sales agreement with a financial institution, pursuant to which the Company may issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to $ 50.0 million (the Shares), subject to terms and conditions. The Shares will be offered and sold by the Company pursuant to its previously filed and currently effective registration statement on Form S-3. The Shares may only be offered and sold by means of a prospectus, including a prospectus supplement, forming part of the effective registration statement. Sales of the common stock, if any, will be made at market prices by methods deemed to be an “at-the-market offering” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made directly on The Nasdaq Global Market, or any other existing trading market for our common stock. On March 7, 2022 (the Effective Date), the Company entered into a purchase agreement with Lincoln Park Capital Fund, LLC (Lincoln Park), pursuant to which Lincoln Park has committed to purchase up to $ 50.0 million of the Company's common stock (the Purchase Agreement). Under the terms and subject to the conditions of the Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase up to $ 50.0 million of the Company’s common stock. Such sales of common stock by the Company, if any, will be subject to certain limitations, and may occur from time to time, at the Company’s sole discretion, over the 36-month period commencing on the Effective Date. The number of shares the Company may sell to Lincoln Park on any single business day in a regular purchase is 50,000 shares, but that amount may be increased up to 100,000 shares, depending upon the market price of the Company’s common stock at the time of sale and subject to a maximum limit of $ 1.5 million per regular purchase. The purchase price per share for each such regular purchase will be based on prevailing market prices of the Company’s common stock immediately preceding the time of sale as computed under the Purchase Agreement. In addition to regular purchases, the Company may also direct Lincoln Park to purchase other amounts as accelerated purchases or as additional accelerated purchases. Under applicable rules of the Nasdaq Capital Market, in no event may the Company issue or sell to Lincoln Park under the Purchase Agreement more than 19.99% of the shares of the Company’s common stock outstanding immediately prior to the execution of the Purchase Agreement (the Exchange Cap), unless (i) the Company obtains stockholder approval to issue shares of common stock in excess of the Exchange Cap or (ii) the average price of all applicable sales of common stock to Lincoln Park under the Purchase Agreement equals or exceeds $2.20 per share, such that issuances and sales of the common stock to Lincoln Park under the Purchase Agreement would be exempt from the Exchange Cap limitation under applicable Nasdaq rules. Lincoln Park has no right to require the Company to sell any shares of common stock to Lincoln Park, but Lincoln Park is obligated to make purchases as the Company directs, subject to certain conditions. In all instances, the Company may not sell shares of its common stock to Lincoln Park under the Purchase Agreement if doing so would result in Lincoln Park beneficially owning more than 9.99 % of its common stock. Actual sales of shares of common stock to Lincoln Park under the Purchase Agreement will depend on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, the trading price of the common stock and determinations by the Company as to the appropriate sources of funding for the Company and its operations. The net proceeds, if any, under the Purchase Agreement will depend on the frequency and prices at which the Company sells shares of its common stock to Lincoln Park. The Company intends to use any net proceeds from the sale of its common stock to Lincoln Park to advance its growth strategy and for general corporate purposes. On the Effective Date, the Company issued 184,275 shares of common stock to Lincoln Park as a commitment fee (the Initial Commitment Shares) for which the Company did not receive consideration and, upon the available amount being reduced to an amount equal to or less than $ 20.0 million, the Company will be required to issue 61,425 shares (the Additional Commitment Shares and together with the Initial Commitment Shares, collectively, the Commitment Shares). The Initial Commitment Shares issued were valued at $ 600,000 and are included on the balance sheet in 'Other long-term assets'. In addition to the Initial Commitment Shares, the Company recorded $ 129,000 of due diligence expenses and legal fees as deferred offering costs. The deferred offering costs will be charged against 'Additional paid-in capital' upon f uture proceeds from the sale of common stock under the Purchase Agreement. During the three and six months ended June 30, 2022 , $ 18,000 of deferred offering costs were charged against 'Additional paid-in capital', respectively. As of June 30, 2022 , $ 711,000 of deferred offeri ng costs remain. The Purchase Agreement may be terminated by the Company at any time, at its sole discretion, without any cost or penalty, by giving one business day notice to Lincoln Park to terminate the Purchase Agreement. Lincoln Park has covenanted not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of the common stock. Although the Company has agreed to reimburse Lincoln Park for a limited portion of the fees it incurred in connection with the Purchase Agreement, the Company did not pay any additional amounts to reimburse or otherwise compensate Lincoln Park in connection with the transaction, other than the issuance of the Commitment Shares. During the three and six months ended June 30, 2022 , the Company raised approximately $ 2.9 million and $ 4.5 million, respectively ($ 2.8 million and $ 4.0 million, respectively, after deducting underwriting discounts and commissions and offering expenses payable), in gross proceeds from the sale of 1,419,139 and 2,127,891 common shares at a weighted average price per share of $ 2.03 and $ 2.11 , respectively, under these programs. As of June 30, 2022 , the Company had remaining available capacity for share issuances of approximately $ 29.9 million under the at-the-market facility and up to $ 49.2 mi llion under the LPC facility, each subject to the restrictions and limitations of the underlying facilities, as applicable. Subscription Agreements On April 7, 2022, the Company entered into subscription agreements (the Subscription Agreements) with a consortium of investors (the Investors), including three members of our Board of Directors and other existing shareholders of the Company, for the issuance and sale by the Company of 6,508,376 shares of the Company’s common stock (the Shares) in an offering (the Private Placement). The three members of our Board of Directors acquired an aggregate of 3,631,284 shares pursuant to the form of a Subscription Agreement that did not include any registration rights. The remaining 2,877,092 shares were acquired by others pursuant to the form of a Subscription Agreement whereby the Company agreed to file, subject to certain exceptions, a shelf registration statement with respect to resales of such shares with the Securities and Exchange Commission no later than 60 days from April 7, 2022, which the Company filed on June 6, 2022. Pursuant to the Subscription Agreements, the Investors purchased shares at a purchase price (determined in accordance with Nasdaq rules relating to the “Minimum Value” of the Company’s common stock) of $ 1.79 per share, which is equal to the closing price of the Company's common stock on April 7, 2022, for an aggregate purchase price of approximately $ 11.7 million. The Subscription Agreements include customary representations, warranties and covenants by the parties to the agreement. Warrants During 2018, the Company issued warrants to purchase shares of convertible preferred stock in conjunction with the sale of certain convertible preferred shares and issuance of debt. The Company issued to the lender a warrant to purchase 613,333 shares of Series G convertible preferred stock, at an exercise price of $ 0.75 per share, subject to adjustment upon specified dilutive issuances. The warrant was immediately exercisable upon issuance and expires on February 23, 2028 . Through the effective date of the Company’s initial public offering (IPO) in October 2020, the Series G warrants were remeasured to an estimate of fair value using a Black-Scholes pricing model. As a result of the Company’s IPO, the preferred stock warrants were automatically converted to warrants to purchase 103,326 shares of common stock with a weighted average exercise price of $ 4.46 and were also transferred to additional paid-in capital. All common stock warrants remain outstanding as of June 30, 2022 . Note 9 – Revenue and Accounts Receivable Credit Concentration We derive our revenue from two primary sources: (i) providing diagnostic testing in the clinical setting (Diagnostic tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, clinical trial testing, development and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics (Services). Diagnostic test revenues consist of blood-based lung tests and COVID-19 tests, which are recognized in the amount expected to be received in exchange for diagnostic tests when the diagnostic tests are delivered. The Company conducts diagnostic tests and delivers the completed test results to the prescribing physician or patient, as applicable. The fees for diagnostic tests are billed either to a third party such as Medicare, medical facilities, commercial insurance payers, or to the patient. The Company determines the transaction price related to its diagnostic test contracts by considering the nature of the payer and historical price concessions granted to groups of customers. For diagnostic test revenue, the Company estimates the transaction price, which is the amount of consideration it expects to be entitled to receive in exchange for providing services based on its historical collection experience, using a portfolio approach. The Company recognizes revenues for diagnostic tests upon delivery of the tests to the physicians requesting the tests or patient, as applicable. Services revenue consists of on-market tests, pipeline tests, custom diagnostic testing, and other scientific services for a purpose as defined by any individual customer, which is often with biopharmaceutical companies. The performance obligations and related revenue for these sales is defined by a written agreement between the Company and the customer. These services are generally completed upon the delivery of testing results, or other contractually defined milestone(s), to the customer. Revenue for these services is recognized upon delivery of the completed test results, or upon completion of the contractual milestone(s). Revenues consisted of the following (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Diagnostic tests $ 10,206 $ 10,838 $ 15,839 $ 38,033 Services 744 1,047 1,659 2,718 Total revenue $ 10,950 $ 11,885 $ 17,498 $ 40,751 Deferred Revenue Deferred revenue consists of cash payments from customers received in advance of delivery. As test results are delivered, the Company recogn izes the deferred revenue in ‘Revenues’ in the statements of operations. Of the $ 1.9 million in ‘Deferred revenue’ recorded in the balance sheet as of December 31, 2021, $ 0.8 million was recognized in revenues during the six months ended June 30, 2022, $ 0.3 million was added to ‘Deferred revenue’ for up-front cash payments received for which the revenue recognition criteria have not been met and $ 0.8 million was reclassified from non-current deferred revenue. The ‘Deferred revenue’ of $ 2.2 million recorded in the balance sheet as of June 30, 2022 is expected to be recognized in revenues over the next twelve months as test results are delivered and services are performed. As of June 30, 2022 and December 31, 2021, the Company had zero and $ 0.8 million in non-current deferred revenue, respectively, recorded within ‘Other long-term liabilities’ in the balance sheets which represent amounts to be recognized in excess of twelve months from the respective balance sheet date. The Company’s customers in excess of 10% of total revenue both pertain to our COVID-19 diagnostic testing services, and their related revenue as a percentage of total revenue were as follows: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 The State of Colorado 22 % — 16 % — The Big Ten Conference — 40 % — 53 % In addition to the above table, we collect reimbursement on behalf of customers covered by Medicare, which accounted for 28 % and 33 % of the Compa ny’s total revenue for the three and six months ended June 30, 2022 , respectively, compared to 56 % for both the three and six months ended June 30, 2021. The Company is subject to credit risk from its accounts receivable related to services provided to its customers. The Company does not perform evaluations of customers' financial condition and does not require collateral. The Company’s third-party payors and other customers in excess of 10% of accounts receivable, and their related accounts receivable as a percentage of total accounts receivable were as follows: As of June 30, 2022 December 31, 2021 The State of Colorado 27 % — Medicare 26 % 30 % Janssen Research and Development, LLC 11 % 14 % LabCorp DD (formerly Covance) 4 % 11 % Note 10 – Share-Based Compensation The Company’s share-based compensation awards are issued under the 2020 Equity Incentive Plan (2020 Plan), the predecessor 2016 Equity Incentive Plan (2016 Plan) and 2006 Equity Incentive Plan (2006 Plan). Any awards that expire or are forfeited under the 2016 Plan or 2006 Plan become available for issuance under the 2020 Plan. As of June 30, 2022 , 29,740 sh ares of common stock remained available for future issuance under the 2020 Plan. Share-Based Compensation Expense Pre-tax share-based compensation expense reported in the Company’s statements of operations was (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Direct costs and expenses $ 13 $ 18 $ 28 $ 18 Research and development 192 86 280 354 Sales, marketing, general and administrative 1,163 435 2,406 1,919 Total $ 1,368 $ 539 $ 2,714 $ 2,291 The remaining unrecognized stock‑based compensation expense for options and restricted stock units was approximately $ 9.4 m illion as of June 30, 2022, and is expected to be amortized to expense over the next 3.1 years. Stock Option Activity Stock option activity during the six months ended June 30, 2022, excluding the Bonus Option Program described below, was (in thousands, except weighted average exercise price and weighted average contractual life): Number of Options Weighted Average Weighted Average Aggregate Intrinsic Value Outstanding ‑ January 1, 2022 2,878 $ 8.08 7.7 $ 6,288 Granted 277 3.37 — — Forfeited/canceled ( 154 ) 8.89 — — Exercised ( 130 ) 0.70 — — Outstanding ‑ June 30, 2022 2,871 $ 7.92 7.5 $ 1,094 Exercisable - June 30, 2022 1,668 $ 6.11 6.8 $ 782 Restricted Stock Unit Activity Restricted stock unit activity during the six months ended June 30, 2022 was (in thousands, except weighted average grant date fair value per share): Number of Shares Weighted Average Outstanding ‑ January 1, 2022 151 $ 5.30 Granted 1,473 2.75 Forfeited/canceled ( 11 ) 3.69 Released ( 138 ) 6.59 Outstanding ‑ June 30, 2022 1,475 $ 2.64 Bonus-to-Options Program As part of the Bonus-to-Options Program (Bonus Option Program), the Company recorded the following activity during the six months ended June 30, 2022 (in thousands, excepted weighted average exercise price and weighted average contractual life): Number of Options Weighted Average Weighted Average Aggregate Intrinsic Value Outstanding ‑ January 1, 2022 373 $ 17.00 7.5 $ 76 Granted 244 2.29 — — Forfeited/canceled ( 14 ) 20.89 — — Exercised — — — — Outstanding ‑June 30, 2022 603 $ 10.96 8.3 Exercisable - June 30, 2022 603 $ 10.96 8.3 The Company accrued $ 0.4 mill ion and $ 0.7 mi llion for the three and six months ended June 30, 2022 , respectively, compared to $ 0.1 million and $ 0.7 million for the three and six months ended June 30, 2021, respectively, related to the estimate of the Bonus Option Program. Options granted, if any, pertaining to the performance of the Bonus Option Program are typically approved and granted in first quarter of the year following completion of the fiscal year. Employee Stock Purchase Plan A tota l of 338,106 shares of our co mmon stock have been reserved for issuance under the Employee Stock Purchase Plan (ESPP). The ESPP provides for successive six-month offering perio ds beginning on September 1st and March 1st of each year. As of June 30, 2022 , 142,680 shares have been issued under the ESPP leaving 195,426 shares remaining for f uture issuance. Note 11 – Net Loss per Common Share Basic earnings per share (EPS) excludes dilution and is computed by dividing net loss attributable to the common stockholders by the weighted-average shares outstanding during the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised, resulting in the issuance of shares of common stock that would then share in the earnings or losses of the Company. In connection with the acquisition of Indi in 2018, the Company recorded contingent consideration (See Note 4 – Fair Value ) for amounts contingently payable to Indi's selling shareholders pursuant to the terms of the asset purchase agreement. The contingent consideration arrangement requires additional consideration to be paid by the Company to Indi upon attainment of a three-consecutive month gross margin target of $ 2.0 million within the seven-year period after the acquisition date. When the gross margin target was met, the Company was required to issue 2,520,108 shares of common stock. The Company met the gross margin target of $ 2.0 million for three consecutive months during the three months ended June 30, 2021. As a result of the achievement of the gross margin target, the Company included the 2,520,108 shares of common stock in the calculation of weighted-average shares outstanding used in computing basic and diluted net loss per share for the three and six months ended June 30, 2021. In August 2021, the Company entered into an amendment of the original agreement in which the Company has agreed to forgo the issuance of its Common Stock. Therefore, these shares are not included in the statements of stockholders' equity or shares issued and outstanding in the balance sheets and are not included in our earnings per share calculation subsequent to August 2021. Basic and diluted loss per share for the three and six months ended June 30, 2022 and 2021 were (in thousands, except per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Numerator Net loss attributable to common stockholders $ ( 15,824 ) $ ( 11,402 ) $ ( 31,410 ) $ ( 18,363 ) Denominator Weighted-average shares outstanding used 39,239 27,730 35,177 27,020 Net loss per share, basic and diluted $ ( 0.40 ) $ ( 0.41 ) ( 0.89 ) ( 0.68 ) The following outstanding common stock equivalents were excluded from diluted net loss attributable to common stockholders for the periods presented because inclusion would be anti-dilutive (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Options to purchase common stock 3,474 2,874 3,474 2,874 Shares committed under ESPP 44 — 44 — Warrants 103 103 103 103 Restricted stock units 1,475 119 1,475 119 Total 5,096 3,096 5,096 3,096 Note 12 - Income Taxes Since inception, the Company has incurred net taxable losses, and accordingly, no provision for income taxes has been recorded. There was no cash paid for income taxes during the three and six months ended June 30, 2022 and 2021 . Note 13 – Commitments and Contingencies Co‑Development Agreement In April 2014 and amended in October 2016, the Company entered into a worldwide agreement with AVEO to develop and commercialize AVEO's hepatocyte growth factor inhibitory antibody ficlatuzumab with the Company's proprietary companion diagnostic test, BDX004, a version of the Company’s serum protein test that is commercially available to help physicians guide treatment decisions for patients with advanced non-small cell lung cancer (NSCLC). Under the terms of the agreement, AVEO will conduct a proof of concept (POC) clinical study of ficlatuzumab for NSCLC in which BDX004 will be used to select clinical trial subjects (the NSCLC POC Trial). Under the agreement, the Company and AVEO would share equally in the costs of the NSCLC POC Trial, and each would be responsible for 50 % of development and regulatory costs associated with all future clinical trials agreed upon by the Company and AVEO. The Company and AVEO continue to conduct POC clinical trials of ficlatuzumab in combination with BDX004. In September 2020, the Company exercised its opt-out right with AVEO for the payment of 50 % of development and regulatory costs for ficlatuzumab effective December 2, 2020 (the Effective Date). In September 2021, AVEO announced that the FDA has granted Fast Track Designation (FTD) to ficlatuzumab for the treatment of patients with relapsed or recurrent head and neck squamous cell carcinoma. In November 2021 AVEO also announced plans to initiate a potential registrational Phase 3 clinical trial for ficlatuzumab in the first half of 2023. The Compan y had $ 0.1 million i n remaining obligations related to the AVEO agreement as of June 30, 2022 . Following the Effective Date, the Company is entitled to a 10 % royalty of net sales of ficlatuzumab and 25 % of license income generated from the licensing of ficlatuzumab from AVEO. There were no expenses related to this agreement for the three and six months ended June 30, 2022 and 2021. License Agreements In August 2019, we entered into a non-exclusive license agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) (the Bio-Rad License). Under the terms of the Bio-Rad License, the Company received a non-exclusive license, without the right to grant sublicenses, to utilize certain of Bio-Rad’s intellectual property, machinery, materials, reagents, supplies and know-how necessary for the performance of Droplet Digital PCR™ (ddPCR) in cancer detection testing for third parties in the United States. The Company also agreed to purchase all of the necessary supplies and reagents for such testing exclusively from Bio-Rad, pursuant to a separately executed supply agreement (the Supply Agreement) with Bio-Rad. As further consideration for the non-exclusive license, the Company agreed to pay a royalty of 2.5 % on the net revenue received for the performance of such ddPCR testing collected from third parties. On May 24, 2021, the Company entered into the First Amendment to the Non-Exclusive License Agreement with Bio-Rad which amended the Bio-Rad License such that, effective May 1, 2021, the Company will no longer pay a royalty of 2.5 % on the net revenue received for the performance of such ddPCR testing collected from third parties. The Bio-Rad License expires in August 2024 . Either party may terminate for the other’s uncured material breach or bankruptcy events. Bio-Rad may terminate the Bio-Rad License if the Company does not purchase licensed products under the Supply Agreement for a consecutive twelve-month period or for any material breach by us of the Supply Agreement. There were no expenses related to this agreement for the three and six months ended June 30, 2022 and 2021. On May 13, 2021 (Effective Date), we reached agreement with CellCarta Biosciences Inc. (formerly “Caprion Biosciences, Inc.”) (the CellCarta License) on a new royalty bearing license agreement for the Nodify XL2 test. The parties agreed to terminate all prior agreements and replace with this new arrangement, which has a 1 % fee on net sales made from the first commercial sale of the Nodify XL2 test to the Effective Date as an upfront make-good payment covering past royalties due and a royalty rate of 0.675 % on future Nodify XL2 test net sales worldwide for 15 years from the first commercial sale, ending in 2034 . Royalty expense under the CellCarta License for the three and six months ended June 30, 2022 and 2021 was insignificant. As part of the acquisition of the assets of Oncimmune USA, the Company entered into several agreements to govern the relationship between the parties. The Company agreed to a license agreement and royalty payment related to an acquired diagnostic test of 8 % of recognized revenue for non-screening tests up to an annual minimum volume and 5 % thereafter, with an escalating minimum through the first four years of sales . Royalty expenses were $ 0.2 million and $ 0.4 million for the three and six months ended June 30, 2022 , respectively, compared to $ 0.1 million and $ 0.3 million for the three and six months ended June 30, 2021, respectively. Litigation, Claims and Assessments From time to time, we may become involved in legal proceedings or investigations which could have an adverse impact on our reputation, business and financial condition and divert the attention of our management from the operation of our business. We are not presently a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, results of operations, financial condition, or cash flows. Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. Biodesix, Inc. is referred to throughout this Quarterly Report on Form 10-Q for the period ended June 30, 2022 (Form 10-Q) as “we”, “us”, “our” or the “Company”. The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2021 (Form 10-K) and the Condensed Financial Statements as of June 30, 2022 and for the three and six months ended June 30, 2022 and 2021, included in Part I, Item 1 of this Form 10-Q, which provide additional information regarding our financial position, results of operations and cash flows. To the extent that the following MD&A contains statements which are not of a historical nature, such statements are forward-looking statements, which involve risks and uncertainties, including but not limited to those set forth under the caption “Special Note Regarding Forward-Looking Statements” and Item 1A “Risk Factors” of Part II in this Quarterly Report on Form 10-Q and those discussed in our other filings with the Securities and Exchange Commission (SEC), including the risks described in Item 1A “Risk Factors” of Part I of our Annual Report on Form 10-K for the year ended December 31, 2021, which was filed on March 14, 2022. The following MD&A discussion is provided to supplement the Condensed Financial Statements as of June 30, 2022 and 2021 and for the three and six months then ended included in Part I, Item 1 of this Quarterly Report on Form 10-Q. We intend for this discussion to provide you with information that will assist you in understanding our financial statements, the changes in key items in those financial statements from period to period, and the primary factors that accounted for those changes. Data for the three and six months ended June 30, 2022 and 2021 has been derived from our unaudited condensed financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q. Overview We are a leading data-driven diagnostic solutions company leveraging state of the art technologies with our proprietary AI platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. By combining a technology multi-omic approach with a holistic view of the patient’s disease state, we believe our solutions provide physicians with greater insights to help personalize their patient’s care and meaningfully improve disease detection, evaluation, and treatment. Our unique approach to precision medicine provides timely and actionable clinical information, which we believe helps improve overall patient outcomes and lowers the overall healthcare cost by reducing the use of ineffective and unnecessary treatments and procedures. In addition to our diagnostic tests, we provide biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. Our core belief is that no single technology will answer all clinical questions that we encounter. Therefore, we employ multiple technologies, including genomics, transcriptomics, proteomics, and radiomics, and leverage our proprietary AI-based Diagnostic Cortex® platform to discover innovative diagnostic tests for clinical use. The Diagnostic Cortex is an extensively validated deep learning platform optimized for the discovery of diagnostic tests, which we believe overcomes standard machine learning challenges faced in life sciences research. Our data-driven and multi-omic approach is designed to enable us to discover diagnostic tests that answer critical clinical questions faced by physicians, researchers, and biopharmaceutical companies. We continuously incorporate new market insights and patient data to enhance our platform through a data-driven learning loop. We regularly engage with our customers, key opinion leaders, and scientific experts to stay ahead of the rapidly evolving diagnostic treatment landscape to identify additional clinical unmet needs where a diagnostic test could help improve patient care. Additionally, we incorporate clinical and molecular profiling data from our commercial clinical testing, research studies, clinical trials, and biopharmaceutical customers or academic partnerships, to continue to advance our platform. We have a variety of samples with associated data in our biobank, including tumor profiles and immune profiles, which are used for both internal and external research and development initiatives. We have commercialized eight diagnostic tests which are currently available for use by physicians. Our Nodify XL2 and Nodify CDT tests, marketed as part of the Nodify Lung Nodule Risk Assessment testing strategy, assess the risk of lung cancer to help identify the most appropriate treatment pathway. We believe we are the only company to offer two commercial blood-based tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules. Our GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests, marketed as the IQLung testing strategy, are used following diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient’s immune system to establish the patient’s prognosis and help guide treatment decisions. The GeneStrat targeted tumor profiling test and the VeriStrat immune profiling test now have a 36-hour average turnaround time, down from the previous 72-hour average turnaround time, providing physicians with timely results to facilitate treatment decisions. The GeneStrat NGS test is our 72-hour average turnaround time blood-based NGS test, which was launched in November 2021 to a select group of physicians, with national launch in January 2022. The 52-gene panel includes guideline recommended mutations to help physicians treating advanced-stage lung cancer patients identify all four major mutation classes and genes, such as EGFR, ALK, KRAS, MET, NTRK, ERBB2, and others, and delivers them in an expedited timeframe so patient treatment can begin sooner. In

Share-Based Compensation

Share-Based Compensation	6 Months Ended
	Jun. 30, 2022
Share-based Payment Arrangement [Abstract]
Share-Based Compensation	Note 10 – Share-Based Compensation The Company’s share-based compensation awards are issued under the 2020 Equity Incentive Plan (2020 Plan), the predecessor 2016 Equity Incentive Plan (2016 Plan) and 2006 Equity Incentive Plan (2006 Plan). Any awards that expire or are forfeited under the 2016 Plan or 2006 Plan become available for issuance under the 2020 Plan. As of June 30, 2022 , 29,740 sh ares of common stock remained available for future issuance under the 2020 Plan. Share-Based Compensation Expense Pre-tax share-based compensation expense reported in the Company’s statements of operations was (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Direct costs and expenses $ 13 $ 18 $ 28 $ 18 Research and development 192 86 280 354 Sales, marketing, general and administrative 1,163 435 2,406 1,919 Total $ 1,368 $ 539 $ 2,714 $ 2,291 The remaining unrecognized stock‑based compensation expense for options and restricted stock units was approximately $ 9.4 m illion as of June 30, 2022, and is expected to be amortized to expense over the next 3.1 years. Stock Option Activity Stock option activity during the six months ended June 30, 2022, excluding the Bonus Option Program described below, was (in thousands, except weighted average exercise price and weighted average contractual life): Number of Options Weighted Average Weighted Average Aggregate Intrinsic Value Outstanding ‑ January 1, 2022 2,878 $ 8.08 7.7 $ 6,288 Granted 277 3.37 — — Forfeited/canceled ( 154 ) 8.89 — — Exercised ( 130 ) 0.70 — — Outstanding ‑ June 30, 2022 2,871 $ 7.92 7.5 $ 1,094 Exercisable - June 30, 2022 1,668 $ 6.11 6.8 $ 782 Restricted Stock Unit Activity Restricted stock unit activity during the six months ended June 30, 2022 was (in thousands, except weighted average grant date fair value per share): Number of Shares Weighted Average Outstanding ‑ January 1, 2022 151 $ 5.30 Granted 1,473 2.75 Forfeited/canceled ( 11 ) 3.69 Released ( 138 ) 6.59 Outstanding ‑ June 30, 2022 1,475 $ 2.64 Bonus-to-Options Program As part of the Bonus-to-Options Program (Bonus Option Program), the Company recorded the following activity during the six months ended June 30, 2022 (in thousands, excepted weighted average exercise price and weighted average contractual life): Number of Options Weighted Average Weighted Average Aggregate Intrinsic Value Outstanding ‑ January 1, 2022 373 $ 17.00 7.5 $ 76 Granted 244 2.29 — — Forfeited/canceled ( 14 ) 20.89 — — Exercised — — — — Outstanding ‑June 30, 2022 603 $ 10.96 8.3 Exercisable - June 30, 2022 603 $ 10.96 8.3 The Company accrued $ 0.4 mill ion and $ 0.7 mi llion for the three and six months ended June 30, 2022 , respectively, compared to $ 0.1 million and $ 0.7 million for the three and six months ended June 30, 2021, respectively, related to the estimate of the Bonus Option Program. Options granted, if any, pertaining to the performance of the Bonus Option Program are typically approved and granted in first quarter of the year following completion of the fiscal year. Employee Stock Purchase Plan A tota l of 338,106 shares of our co mmon stock have been reserved for issuance under the Employee Stock Purchase Plan (ESPP). The ESPP provides for successive six-month offering perio ds beginning on September 1st and March 1st of each year. As of June 30, 2022 , 142,680 shares have been issued under the ESPP leaving 195,426 shares remaining for f uture issuance.

Net Loss per Common Share

Net Loss per Common Share	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Net Loss per Common Share	Note 11 – Net Loss per Common Share Basic earnings per share (EPS) excludes dilution and is computed by dividing net loss attributable to the common stockholders by the weighted-average shares outstanding during the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised, resulting in the issuance of shares of common stock that would then share in the earnings or losses of the Company. In connection with the acquisition of Indi in 2018, the Company recorded contingent consideration (See Note 4 – Fair Value ) for amounts contingently payable to Indi's selling shareholders pursuant to the terms of the asset purchase agreement. The contingent consideration arrangement requires additional consideration to be paid by the Company to Indi upon attainment of a three-consecutive month gross margin target of $ 2.0 million within the seven-year period after the acquisition date. When the gross margin target was met, the Company was required to issue 2,520,108 shares of common stock. The Company met the gross margin target of $ 2.0 million for three consecutive months during the three months ended June 30, 2021. As a result of the achievement of the gross margin target, the Company included the 2,520,108 shares of common stock in the calculation of weighted-average shares outstanding used in computing basic and diluted net loss per share for the three and six months ended June 30, 2021. In August 2021, the Company entered into an amendment of the original agreement in which the Company has agreed to forgo the issuance of its Common Stock. Therefore, these shares are not included in the statements of stockholders' equity or shares issued and outstanding in the balance sheets and are not included in our earnings per share calculation subsequent to August 2021. Basic and diluted loss per share for the three and six months ended June 30, 2022 and 2021 were (in thousands, except per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Numerator Net loss attributable to common stockholders $ ( 15,824 ) $ ( 11,402 ) $ ( 31,410 ) $ ( 18,363 ) Denominator Weighted-average shares outstanding used 39,239 27,730 35,177 27,020 Net loss per share, basic and diluted $ ( 0.40 ) $ ( 0.41 ) ( 0.89 ) ( 0.68 ) The following outstanding common stock equivalents were excluded from diluted net loss attributable to common stockholders for the periods presented because inclusion would be anti-dilutive (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Options to purchase common stock 3,474 2,874 3,474 2,874 Shares committed under ESPP 44 — 44 — Warrants 103 103 103 103 Restricted stock units 1,475 119 1,475 119 Total 5,096 3,096 5,096 3,096

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Note 12 - Income Taxes Since inception, the Company has incurred net taxable losses, and accordingly, no provision for income taxes has been recorded. There was no cash paid for income taxes during the three and six months ended June 30, 2022 and 2021 .

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 13 – Commitments and Contingencies Co‑Development Agreement In April 2014 and amended in October 2016, the Company entered into a worldwide agreement with AVEO to develop and commercialize AVEO's hepatocyte growth factor inhibitory antibody ficlatuzumab with the Company's proprietary companion diagnostic test, BDX004, a version of the Company’s serum protein test that is commercially available to help physicians guide treatment decisions for patients with advanced non-small cell lung cancer (NSCLC). Under the terms of the agreement, AVEO will conduct a proof of concept (POC) clinical study of ficlatuzumab for NSCLC in which BDX004 will be used to select clinical trial subjects (the NSCLC POC Trial). Under the agreement, the Company and AVEO would share equally in the costs of the NSCLC POC Trial, and each would be responsible for 50 % of development and regulatory costs associated with all future clinical trials agreed upon by the Company and AVEO. The Company and AVEO continue to conduct POC clinical trials of ficlatuzumab in combination with BDX004. In September 2020, the Company exercised its opt-out right with AVEO for the payment of 50 % of development and regulatory costs for ficlatuzumab effective December 2, 2020 (the Effective Date). In September 2021, AVEO announced that the FDA has granted Fast Track Designation (FTD) to ficlatuzumab for the treatment of patients with relapsed or recurrent head and neck squamous cell carcinoma. In November 2021 AVEO also announced plans to initiate a potential registrational Phase 3 clinical trial for ficlatuzumab in the first half of 2023. The Compan y had $ 0.1 million i n remaining obligations related to the AVEO agreement as of June 30, 2022 . Following the Effective Date, the Company is entitled to a 10 % royalty of net sales of ficlatuzumab and 25 % of license income generated from the licensing of ficlatuzumab from AVEO. There were no expenses related to this agreement for the three and six months ended June 30, 2022 and 2021. License Agreements In August 2019, we entered into a non-exclusive license agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) (the Bio-Rad License). Under the terms of the Bio-Rad License, the Company received a non-exclusive license, without the right to grant sublicenses, to utilize certain of Bio-Rad’s intellectual property, machinery, materials, reagents, supplies and know-how necessary for the performance of Droplet Digital PCR™ (ddPCR) in cancer detection testing for third parties in the United States. The Company also agreed to purchase all of the necessary supplies and reagents for such testing exclusively from Bio-Rad, pursuant to a separately executed supply agreement (the Supply Agreement) with Bio-Rad. As further consideration for the non-exclusive license, the Company agreed to pay a royalty of 2.5 % on the net revenue received for the performance of such ddPCR testing collected from third parties. On May 24, 2021, the Company entered into the First Amendment to the Non-Exclusive License Agreement with Bio-Rad which amended the Bio-Rad License such that, effective May 1, 2021, the Company will no longer pay a royalty of 2.5 % on the net revenue received for the performance of such ddPCR testing collected from third parties. The Bio-Rad License expires in August 2024 . Either party may terminate for the other’s uncured material breach or bankruptcy events. Bio-Rad may terminate the Bio-Rad License if the Company does not purchase licensed products under the Supply Agreement for a consecutive twelve-month period or for any material breach by us of the Supply Agreement. There were no expenses related to this agreement for the three and six months ended June 30, 2022 and 2021. On May 13, 2021 (Effective Date), we reached agreement with CellCarta Biosciences Inc. (formerly “Caprion Biosciences, Inc.”) (the CellCarta License) on a new royalty bearing license agreement for the Nodify XL2 test. The parties agreed to terminate all prior agreements and replace with this new arrangement, which has a 1 % fee on net sales made from the first commercial sale of the Nodify XL2 test to the Effective Date as an upfront make-good payment covering past royalties due and a royalty rate of 0.675 % on future Nodify XL2 test net sales worldwide for 15 years from the first commercial sale, ending in 2034 . Royalty expense under the CellCarta License for the three and six months ended June 30, 2022 and 2021 was insignificant. As part of the acquisition of the assets of Oncimmune USA, the Company entered into several agreements to govern the relationship between the parties. The Company agreed to a license agreement and royalty payment related to an acquired diagnostic test of 8 % of recognized revenue for non-screening tests up to an annual minimum volume and 5 % thereafter, with an escalating minimum through the first four years of sales . Royalty expenses were $ 0.2 million and $ 0.4 million for the three and six months ended June 30, 2022 , respectively, compared to $ 0.1 million and $ 0.3 million for the three and six months ended June 30, 2021, respectively. Litigation, Claims and Assessments From time to time, we may become involved in legal proceedings or investigations which could have an adverse impact on our reputation, business and financial condition and divert the attention of our management from the operation of our business. We are not presently a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, results of operations, financial condition, or cash flows.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X for interim financial information and reflect all adjustments necessary to state fairly the Company’s financial position, results of operations and cash flows for the interim periods presented. All such adjustments are of a normal recurring nature. Results for interim periods are not indicative of the results for the entire fiscal year. The accompanying Condensed Financial Statements should be read in conjunction with the audited Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. Certain information and footnote disclosures, including significant accounting policies, normally included in fiscal year financial statements prepared in accordance with accounting principles generally accepted in the U.S. (GAAP) have been condensed or omitted. The Condensed Balance Sheet as of December 31, 2021 was derived from the audited financial statements. As of June 30, 2022, we maintained cash and cash equivalents of $ 28.7 million, inclusive of $ 5.1 million in restricted cash (see Restricted Cash below), and we have $ 23.2 million in outstanding aggregate principal amount on our 2021 Term Loan and Promissory Note One. We have incurred significant losses since inception and, as a result, we have funded our operations to date primarily through the sale of common stock, the sale of convertible preferred stock, the issuance of notes payable, and from our two primary revenue sources: (i) diagnostic testing, which include lung diagnostic testing and COVID-19 testing, and (ii) providing biopharmaceutical companies with development and testing services. In accordance with Accounting Standards Update 2014-15 (ASC Topic 205-40), Presentation of Financial Statements - Going Concern: Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern , the Company is required to evaluate whether there is substantial doubt about its ability to continue as a going concern each reporting period, including interim periods. In evaluating the Company’s ability to continue as a going concern, management projected its cash flow sources, including the debt and equity funding and amendments to the 2021 Term Loan and Integrated Diagnostics, Inc. (Indi) Agreement, and evaluated the conditions and events that could raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these financial statements were issued. Management considered the Company’s current projections of future cash flows, current financial condition, sources of liquidity and debt obligations for at least one year from the date of issuance of this Form 10-Q in considering whether it has the ability to meet its obligations. Our ability to meet our obligations as they come due may be impacted by our ability to remain compliant with financial covenants in our loan agreements (see Note 6 – Debt ) or to obtain waivers or amendments that impact the related covenants. Due to the continued uncertainty caused by the COVID-19 pandemic, significant risks remain with respect to our ability to meet these thresholds and any material adverse effect on our revenues, income and expenses could impact our ability to maintain compliance with these covenants. Based on our current operating plan, unless we continue to raise additional capital (debt or equity) or obtain a waiver from complying with such financial covenants, we expect that we will be unable to maintain our financial covenants under our existing loan agreements during the next twelve months, which could result in an Event of Default, as defined, causing an acceleration and repayment of the outstanding balances. We have taken steps to improve our liquidity through raising debt and equity capital during 2022, amendments to our 2021 Term Loan, and have also undertaken several proactive measures to mitigate the financial and operational impacts of the COVID-19 pandemic through the reduction of planned capital expenditures and certain operating expenses but we do not expect that these actions alone will be sufficient to maintain our financial covenants. During the three months ended June 30, 2022, we entered into a $ 25.0 million debt facility with funding for up to $ 25.0 million in two tranches. On May 9, 2022, we closed on the first tranche for gross proceeds of $ 15.0 million (approximately $ 12.8 million, net, after deducting debt issuance costs and original issue discounts (OID)). We also amended the Indi Agreement to delay near term cash requirements and extend the period of milestone payments. To maintain an adequate amount of available liquidity and execute our current operating plan, we will need to continue to raise additional funds from external sources, such as through the issuance of equity or debt securities; however, we have not secured such funding at the time of this filing and any such financing activities are subject to market conditions. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our existing stockholders’ rights. There can be no assurance that additional capital will be available to us or, if available, will be available in sufficient amounts or on terms acceptable to us or on a timely basis. If adequate capital resources are not available on a timely basis, we intend to consider limiting our operations substantially. This limitation of operations could include a hiring freeze, reductions in our workforce, reduction in cash compensation, deferring capital expenditures, and reducing other operating costs. The Company’s revenues, results of operations and cash flows have been materially adversely impacted by the items noted above. Our current operating plan, which is in part determined based on our most recent historical actual results and trends, along with the items noted above, raises substantial doubt about the Company’s ability to continue as a going concern. Our unaudited financial statements have been prepared assuming we will continue as a going concern and do not include any adjustments that might be necessary should we be unable to continue as a going concern.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the balance sheet date and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.
Restricted Cash	Restricted Cash Restricted cash consists of the $ 5.0 million cash collateralized letter of credit for the benefit of the landlord (lessor) to secure the performance of the Company’s obligations under an operating lease agreement with Centennial Valley Properties I, LLC (see Note 7 – Leases ). In addition, $ 0.1 million of deposits related to the Company’s corporate credit cards are reported within ‘Other current assets’ in the balance sheets as of June 30, 2022 and December 31, 2021, respectively .
Concentration of Credit Risk and Other Uncertainties	Concentration of Credit Risk and Other Uncertainties Substantially all of the Company’s cash and cash equivalents are deposited with two major financial institutions in the United States. The Company continually monitors its positions with, and the credit quality of, the financial institution with which it holds cash. Periodically throughout the year, the Company has maintained balances in various operating accounts in excess of federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents. Several of the components for certain of the Company's sample collection kits, test reagents, and test systems are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company's requirements on a timely basis, it could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results. For a discussion of credit risk concentration of accounts receivable as of June 30, 2022 and December 31, 2021, see Note 9 – Revenue and Accounts Receivable Credit Concentration .
Inventory	Inventory Inventory consists primarily of material supplies, which are consumed in the performance of testing services and charged to ‘Direct costs and expenses’. Inventory is stated at cost and reported within ‘Other current assets’ in the balance sheet and was $ 1.9 million an d $ 2.9 million as of June 30, 2022 and December 31, 2021 , respectively.
Fair Value of Financial Instruments	Fair Value of Financial Instruments U.S. GAAP for fair value establishes a hierarchy that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques (market approach, income approach, and cost approach). We utilize a combination of market and income approaches to value our financial instruments. Our financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. Fair value measurements are categorized within the fair value hierarchy based upon the lowest level of the most significant inputs used to determine fair value. The three levels of the hierarchy and the related inputs are as follows: Level Inputs 1 Unadjusted quoted prices in active markets for identical assets and liabilities. 2 Unadjusted quoted prices in active markets for similar assets and liabilities; Unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or Inputs other than quoted prices that are observable for the asset or liability. 3 Unobservable inputs for the asset or liability. The carrying amounts of certain financial instruments including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities. See Note 4 — Fair Value for further discussion related to estimated fair value measurements.
Recently Adopted Accounting Standards	Recently adopted accounting standards In February 2016, the FASB issued Account Standard Update (ASU) No. 2016-2, Leases (ASC 842). This ASU intends to make accounting for leasing activities more transparent and comparable, and requires substantially all leases be recognized by lessees on their balance sheet as a right-of-use asset and corresponding lease liability, including leases accounted for as operating leases. In addition to other related amendments, the FASB issued ASU No. 2018-11, Leases (Topic 842): Targeted Improvements, which offers an additional transition method whereby entities may apply the new leases standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings rather than application of the new leases standard at the beginning of the earliest period presented in the financial statements. T he Company elected this transition method and adopted ASC 842 on January 1, 2022 and as a result, recorded operating lease right-of-use (ROU) assets of $ 1.3 million, including offsetting deferred rent of $ 0.1 million, along with the associated operating lease liabilities of $ 1.3 million. On January 1, 2022, the Company did not have any finance leases. The adoption of ASC 842 did not result in a cumulative effect adjustment to beginning retained earnings, and did not materially affect the Company's statement of operations, statement of stockholders' equity or statement of cash flows for the six months ended June 30, 2022. In addition, the Company elected the following practical expedients permitted under the transition guidance within the new standard: • Package of practical expedients which allows the Company to carry forward the historical lease classification; • Hindsight practical expedient which allows the Company to use hindsight in determining the lease term, in assessing purchase options, and in assessing impairment of ROU assets; • Short-term lease practical expedient which allows the Company to capitalize only those leases with an initial term of twelve months or more, and; • The practical expedient to account for lease and non-lease components (such as common area maintenance, utilities, insurance and taxes) as a single lease component for all classes of underlying assets. Management determines if an arrangement is a lease at inception or upon modification of a contract. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the statements of operations. When determining whether a lease is a finance lease or an operating lease, ASC 842 does not specifically define criteria to determine the “major part of remaining economic life of the underlying asset” and “substantially all of the fair value of the underlying asset.” For lease classification determination, Management continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset. ROU assets represent the Company's right to use an underlying asset for the lease term. Lease liabilities represent the Company's obligation to make lease payments under the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, the Company uses either the rate implicit in the lease or its incremental borrowing rate, as applicable, based on the information available at lease commencement date. The Company applies the estimated incremental borrowing rates on a lease-by-lease level based on the economic environment associated with the lease. The operating lease ROU asset also includes any lease prepayments, net of lease incentives. Certain of the Company's leases include options to extend or terminate the lease. As leases approach maturity, the Company considers various factors such as market conditions and the terms of any renewal and termination options that may exist to determine whether we will renew or terminate the lease, as such, we generally do not include renewal or termination options in our lease terms for calculating our lease liability, as the options allow us to maintain operational flexibility and we are not reasonably certain we will exercise these options at the time of the lease commencement. The Company's lease agreements do not contain any material residual value guarantees or restrictive covenants. Lease expense for lease payments of operating leases is recognized on a straight-line basis over the term of the lease. The Company uses the long-lived assets impairment guidance to determine recognition and measurement of an ROU asset impairment, if any. The Company monitors for events or changes in circumstances that require a reassessment. Additional information and disclosures required by this new standard are contained in Note 7 — Leases . Standards Being Evaluated In June 2016, the FASB issued ASU No. 2016-13 , Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments (ASC Topic 326). This ASU requires measurement and recognition of expected credit losses for financial assets. This guidance will become effective for the Company beginning January 1, 2023 with early adoption permitted. The Company is currently evaluating this guidance and assessing the overall impact on its financial statements.

Fair Value (Tables)

Fair Value (Tables)	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Summary of Fair Value of Outstanding Borrowings	Our borrowing instruments are recorded at their carrying values in the balance sheets, which may differ from their respective fair values. The difference between the carrying value and fair value of outstanding borrowings as of June 30, 2022 is due to the debt issuance costs and OID netted against Promissory Note One entered into with Streeterville Capital, LLC, in May 2022. The carrying value of outstanding borrowings as of December 31, 2021, approximates fair value based on interest rates available at that time for similar borrowings. The table below presents the carrying and fair values of outstanding borrowings, which are classified as Level 2, as of the dates indicated (in thousands): As of June 30, 2022 December 31, 2021 Carrying Value Fair Value Carrying Value Fair Value Borrowings $ 20,367 $ 23,317 $ 10,012 $ 10,012
Schedule of Reported Fair values of Contingent Consideration	The table below presents the reported fair values of contingent consideration, which is classified as Level 3 in the fair value hierarchy, as of the dates indicated (in thousands): Description June 30, 2022 December 31, 2021 Current portion of contingent consideration $ 8,151 $ 17,764 Contingent consideration 22,916 16,028 Total contingent consideration $ 31,067 $ 33,792
Schedule of Changes in Contingent Consideration and Financial Liabilities	The following table presents the changes in contingent consideration for the six months ended June 30, 2022 and 2021 (in thousands): For the six months Level 3 Rollforward 2022 2021 Beginning balances - January 1 $ 33,792 $ 29,932 Changes in fair value — 1,622 Interest expense 966 289 Loss on extinguishment of liabilities 2,934 — Payments of contingent consideration ( 6,625 ) — Ending balances - June 30 $ 31,067 $ 31,843

Supplementary Balance Sheet I_2

Supplementary Balance Sheet Information (Tables)	6 Months Ended
	Jun. 30, 2022
Balance Sheet Related Disclosures [Abstract]
Schedule of Property and Equipment	Property and equipment consist of the following (in thousands): June 30, 2022 December 31, 2021 Lab equipment $ 6,725 $ 6,784 Leasehold improvements 2,365 2,339 Computer equipment 703 700 Furniture and fixtures 341 391 Software 325 600 Vehicles 97 97 Construction in process 411 17 10,967 10,928 Less: accumulated depreciation ( 7,017 ) ( 6,749 ) Total property and equipment, net $ 3,950 $ 4,179
Schedule of Intangible Assets, Excluding Goodwill	Intangible assets, excluding goodwill, consist of the following (in thousands): June 30, 2022 December 31, 2021 Cost Accumulated Net Carrying Value Cost Accumulated Net Carrying Value Intangible assets subject to amortization Patents $ 1,785 $ ( 599 ) $ 1,186 $ 1,755 $ ( 566 ) $ 1,189 Purchased technology 16,900 ( 7,512 ) 9,388 16,900 ( 6,572 ) 10,328 Intangible assets not subject to Trademarks 114 — 114 100 — 100 Total $ 18,799 $ ( 8,111 ) $ 10,688 $ 18,755 $ ( 7,138 ) $ 11,617
Schedule of Future Estimated Amortization Expense of Intangible Assets	Future estimated amortization expense of intangible assets is (in thousands): As of June 30, 2022 Remainder of 2022 $ 986 2023 1,970 2024 1,960 2025 1,954 2026 1,941 2027 and thereafter 1,763 Total $ 10,574
Schedule of Accrued Liabilities	Accrued liabilities consist of the following (in thousands): June 30, 2022 December 31, 2021 Compensation related accruals $ 3,570 $ 4,029 Accrued clinical trial expense 908 870 Other expenses 2,189 2,766 Total accrued liabilities $ 6,667 $ 7,665

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Summary of Long-term Notes Payable	Long-term notes payable were as follows (in thousands): June 30, 2022 December 31, 2021 Promissory Note One $ 16,164 $ — 2021 Term Loan 7,000 10,000 Other 153 75 Unamortized debt discount and issuance costs ( 2,950 ) ( 63 ) 20,367 10,012 Less: current maturities 11,771 19 Long-term notes payable $ 8,596 $ 9,993
Scheduled Principal Repayments (Maturities) of Long-term Obligations	Scheduled principal repayments (maturities) of long-term obligations were as follows (in thousands): As of June 30, 2022 Remainder of 2022 $ 7,023 2023 14,616 2024 1,647 2025 25 2026 6 2027 and thereafter — Total $ 23,317

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Summary of Future Minimum Lease Payments for Operating Leases	Future minimum lease payments associated with our operating leases were as follows (in thousands): As of June 30, 2022 Remainder of 2022 (1) $ ( 9,732 ) 2023 (1) ( 8,121 ) 2024 2,619 2025 3,710 2026 3,979 2027 and thereafter 36,327 Total future minimum lease payments 28,782 Less amount representing interest ( 24,565 ) Total lease liabilities $ 4,217
Summary of Future Minimum Lease Payments for Operating Lease Obligations	Future minimum lease payments, which do not include amounts for common area maintenance, insurance, or taxes, for operating lease obligations in accordance with ASC 840 - Leases were as follows (in thousands): As of December 31, 2021 2022 $ 775 2023 149 2024 9 2025 3 2026 1 2027 and thereafter — Total $ 937

Revenue and Accounts Receivable

Revenue and Accounts Receivable Credit Concentration (Tables)	6 Months Ended
	Jun. 30, 2022
Revenue from Contract with Customer [Abstract]
Summary of Revenue	Revenues consisted of the following (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Diagnostic tests $ 10,206 $ 10,838 $ 15,839 $ 38,033 Services 744 1,047 1,659 2,718 Total revenue $ 10,950 $ 11,885 $ 17,498 $ 40,751
Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers	The Company’s customers in excess of 10% of total revenue both pertain to our COVID-19 diagnostic testing services, and their related revenue as a percentage of total revenue were as follows: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 The State of Colorado 22 % — 16 % — The Big Ten Conference — 40 % — 53 % The Company’s third-party payors and other customers in excess of 10% of accounts receivable, and their related accounts receivable as a percentage of total accounts receivable were as follows: As of June 30, 2022 December 31, 2021 The State of Colorado 27 % — Medicare 26 % 30 % Janssen Research and Development, LLC 11 % 14 % LabCorp DD (formerly Covance) 4 % 11 %

Share-Based Compensation (Table

Share-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Summary of Pre-tax Share-based Compensation Expense	Pre-tax share-based compensation expense reported in the Company’s statements of operations was (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Direct costs and expenses $ 13 $ 18 $ 28 $ 18 Research and development 192 86 280 354 Sales, marketing, general and administrative 1,163 435 2,406 1,919 Total $ 1,368 $ 539 $ 2,714 $ 2,291
Summary of Stock Option Activity	Stock option activity during the six months ended June 30, 2022, excluding the Bonus Option Program described below, was (in thousands, except weighted average exercise price and weighted average contractual life): Number of Options Weighted Average Weighted Average Aggregate Intrinsic Value Outstanding ‑ January 1, 2022 2,878 $ 8.08 7.7 $ 6,288 Granted 277 3.37 — — Forfeited/canceled ( 154 ) 8.89 — — Exercised ( 130 ) 0.70 — — Outstanding ‑ June 30, 2022 2,871 $ 7.92 7.5 $ 1,094 Exercisable - June 30, 2022 1,668 $ 6.11 6.8 $ 782
Summary of Restricted Stock Units Activity	Restricted stock unit activity during the six months ended June 30, 2022 was (in thousands, except weighted average grant date fair value per share): Number of Shares Weighted Average Outstanding ‑ January 1, 2022 151 $ 5.30 Granted 1,473 2.75 Forfeited/canceled ( 11 ) 3.69 Released ( 138 ) 6.59 Outstanding ‑ June 30, 2022 1,475 $ 2.64
Bonus-To-Options Program
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Summary of Stock Option Activity	As part of the Bonus-to-Options Program (Bonus Option Program), the Company recorded the following activity during the six months ended June 30, 2022 (in thousands, excepted weighted average exercise price and weighted average contractual life): Number of Options Weighted Average Weighted Average Aggregate Intrinsic Value Outstanding ‑ January 1, 2022 373 $ 17.00 7.5 $ 76 Granted 244 2.29 — — Forfeited/canceled ( 14 ) 20.89 — — Exercised — — — — Outstanding ‑June 30, 2022 603 $ 10.96 8.3 Exercisable - June 30, 2022 603 $ 10.96 8.3

Net Loss per Common Share (Tabl

Net Loss per Common Share (Tables)	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Schedule of Computation of Basic and Diluted Loss per Share Attributable to Stockholders	Basic and diluted loss per share for the three and six months ended June 30, 2022 and 2021 were (in thousands, except per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Numerator Net loss attributable to common stockholders $ ( 15,824 ) $ ( 11,402 ) $ ( 31,410 ) $ ( 18,363 ) Denominator Weighted-average shares outstanding used 39,239 27,730 35,177 27,020 Net loss per share, basic and diluted $ ( 0.40 ) $ ( 0.41 ) ( 0.89 ) ( 0.68 )
Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders	The following outstanding common stock equivalents were excluded from diluted net loss attributable to common stockholders for the periods presented because inclusion would be anti-dilutive (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Options to purchase common stock 3,474 2,874 3,474 2,874 Shares committed under ESPP 44 — 44 — Warrants 103 103 103 103 Restricted stock units 1,475 119 1,475 119 Total 5,096 3,096 5,096 3,096

Organization and Description _2

Organization and Description of Business - Additional Information (Details)	6 Months Ended
	Jun. 30, 2022 Test
Organization And Description Of Business [Abstract]
Number of blood based lung cancer test	5
Number of commercial blood-based test	2
Number of SARS-CoV-2 test	3

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)	May 09, 2022	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2020
Summary Of Significant Accounting Policies [Line Items]
Cash and cash equivalents and restricted cash		$ 28,672,000	$ 32,798,000	$ 56,435,000	$ 62,306,000
Restricted cash		5,100
Cash Collateralized Letter of Credit
Summary Of Significant Accounting Policies [Line Items]
Restricted cash		5,000,000
Other Current Assets
Summary Of Significant Accounting Policies [Line Items]
Deposits		100,000	100,000
Inventory		1,900,000	$ 2,900,000
2021 Term Loan and Promissory Note One
Summary Of Significant Accounting Policies [Line Items]
Aggregate principal amount outstanding		23,200,000
First Tranche
Summary Of Significant Accounting Policies [Line Items]
Gross proceeds from debt issuance costs	$ 15,000,000
Proceeds from net of debt issuance costs and original issue discounts	$ 12,800,000
Two Tranche
Summary Of Significant Accounting Policies [Line Items]
Debt facility		25,000,000
Two Tranche | Maximum
Summary Of Significant Accounting Policies [Line Items]
Debt facility		$ 25,000,000

Recently issued Accounting St_2

Recently issued Accounting Standards - Additional Information (Details) - USD ($) $ in Thousands		6 Months Ended
	Jan. 01, 2022	Jun. 30, 2022
Accounting Changes and Error Corrections [Abstract]
Right of use assets	$ 1,300	$ 3,952
Operating Lease, Liability	1,300	$ 4,217
Offsetting deferred rent	$ 100
Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]		Operating Lease, Liability
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]		Right of use assets
Description of lease		For lease classification determination, Management continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset.

Fair Value - Summary of Fair Va

Fair Value - Summary of Fair Value of Outstanding Borrowings (Details) - Fair Value, Recurring - Level 2 - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Carrying Value
Fair Value Liabilities Measured On Recurring Basis [Line Items]
Borrowings	$ 20,367	$ 10,012
Fair Value
Fair Value Liabilities Measured On Recurring Basis [Line Items]
Borrowings	$ 23,317	$ 10,012

Fair Value - Schedule of Report

Fair Value - Schedule of Reported Fair values of Contingent Consideration (Details) - Fair Value, Recurring - Level 3 - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Fair Value Liabilities Measured On Recurring Basis [Line Items]
Total contingent consideration	$ 31,067	$ 33,792
Current Portion of Contingent Consideration
Fair Value Liabilities Measured On Recurring Basis [Line Items]
Total contingent consideration	8,151	17,764
Contingent Consideration
Fair Value Liabilities Measured On Recurring Basis [Line Items]
Total contingent consideration	$ 22,916	$ 16,028

Fair Value - Schedule of Change

Fair Value - Schedule of Changes in Contingent Consideration (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	6 Months Ended
	Apr. 30, 2022	Jun. 30, 2022	Jun. 30, 2022	Jun. 30, 2021
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Loss on extinguishment of liabilities	$ 18	$ 2,952	$ 2,952	$ 728
Fair Value, Recurring | Level 3 | Contingent Consideration
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning balances			33,792	29,932
Changes in fair value				1,622
Interest expense			966	289
Loss on extinguishment of liabilities			(2,934)
Payments of contingent consideration			(6,625)
Ending balances		$ 31,067	$ 31,067	$ 31,843

Fair Value - Additional Informa

Fair Value - Additional Information (Details) $ in Thousands

1 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

Apr. 07, 2022

Dec. 31, 2021 USD ($)

Oct. 31, 2024 USD ($)

Jul. 31, 2024 USD ($) Installment

Apr. 30, 2024 USD ($) Installment

Jul. 31, 2023 USD ($) Installment

Jul. 31, 2022 USD ($)

Apr. 30, 2022 USD ($) Installment

Jun. 30, 2022 USD ($) Installment

Jun. 30, 2021 USD ($)

Jun. 30, 2022 USD ($) Installment

Jun. 30, 2021 USD ($)

Dec. 31, 2018 USD ($) Installment shares

Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Interest expense due to passage of time and fixed payment schedule

$ 1,100

Reduction in contingent consideration

1,000

Loss on debt extinguishment

$ (18)

(2,952)

$ (2,952)

$ (728)

Second Amendment

Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Repayments of Debt

$ 20,000

$ 20,000

Milestone payment

$ 4,600

Interest Expense

Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Loss on debt extinguishment

(2,900)

Interest Expense | Discount Rate

Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Changes in fair value

$ 100

Integrated Diagnostics, Inc

Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Business acquisition description

requires additional consideration to be paid by the Company to such shareholders upon attainment of a three-consecutive month

Business acquisition contingent consideration gross margin target

$ 2,000

$ 2,000

Business acquisition contingent consideration gross margin target period

7 years

Integrated Diagnostics, Inc | Third Amendment to APA Agreement

Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Contingent consideration number of installments | Installment

5

Milestone payment

$ 2,000

Percentage of interest on installment payments

10%

Integrated Diagnostics, Inc | Subsequent Event | Third Amendment to APA Agreement

Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Third milestone and interest payment Made

$ 2,100

Integrated Diagnostics, Inc | Scenario Forecast | Third Amendment to APA Agreement

Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Contingent consideration number of installments | Installment

1

1

3

Milestone payment

$ 8,400

$ 5,000

$ 3,000

Exit fee payment

$ 6,100

Integrated Diagnostics, Inc | Common Stock

Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Business acquisition description

If Indi elected to not exercise its option, the Company had 12 months to repurchase the common stock in two equal and consecutive quarterly cash installments totaling $37.0 million.

Contingent consideration shares | shares

2,520,108

Contingent consideration number of installments | Installment

6

6

8

Contingent consideration arrangements, common shares, redemption amount

$ 4,600

$ 37,000

Repayments of Debt

9,300

Business combination contingent consideration final payment

$ 37,000

Integrated Diagnostics, Inc | Common Stock | Repurchase

Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Contingent consideration number of installments | Installment

2

Contingent consideration cash payment

$ 37,000

Minimum

Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range

11%

Maximum

Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range

16%

Supplementary Balance Sheet I_3

Supplementary Balance Sheet Information - Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 10,967	$ 10,928
Less: accumulated depreciation	(7,017)	(6,749)
Total property and equipment, net	3,950	4,179
Lab Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	6,725	6,784
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment, gross	2,365	2,339
Computer Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	703	700
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Property and equipment, gross	341	391
Software
Property Plant And Equipment [Line Items]
Property and equipment, gross	325	600
Vehicles
Property Plant And Equipment [Line Items]
Property and equipment, gross	97	97
Construction in Process
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 411	$ 17

Supplementary Balance Sheet I_4

Supplementary Balance Sheet Information - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Property Plant And Equipment [Line Items]
Depreciation expense	$ 0.4	$ 0.2	$ 0.8	$ 0.5
Amortization expense of definite-lived intangible assets	$ 0.5		$ 1

Supplementary Balance Sheet I_5

Supplementary Balance Sheet Information - Intangible Assets, Excluding Goodwill (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Finite Lived Intangible Assets [Line Items]
Intangible assets subject to amortization, Net Carrying Value	$ 10,574
Intangible assets, Cost	18,799	$ 18,755
Intangible assets, Accumulated Amortization	(8,111)	(7,138)
Intangible assets, Net Carrying Value	10,688	11,617
Trademarks
Finite Lived Intangible Assets [Line Items]
Intangible assets not subject to amortization, Cost	114	100
Intangible assets not subject to amortization, Net Carrying Value	114	100
Patents
Finite Lived Intangible Assets [Line Items]
Intangible assets subject to amortization, Cost	1,785	1,755
Intangible assets subject to amortization, Accumulated Amortization	599	(566)
Intangible assets subject to amortization, Net Carrying Value	1,186	1,189
Purchased Technology
Finite Lived Intangible Assets [Line Items]
Intangible assets subject to amortization, Cost	16,900	16,900
Intangible assets subject to amortization, Accumulated Amortization	(7,512)	(6,572)
Intangible assets subject to amortization, Net Carrying Value	$ 9,388	$ 10,328

Supplementary Balance Sheet I_6

Supplementary Balance Sheet Information - Schedule of Amortization Related to Remaining Net Intangible Assets Schedule to Amortize (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Balance Sheet Related Disclosures [Abstract]
Remainder of 2022	$ 986
2023	1,970
2024	1,960
2025	1,954
2026	1,941
2027 and thereafter	1,763
Intangible assets subject to amortization, Net Carrying Value	$ 10,574

Supplementary Balance Sheet I_7

Supplementary Balance Sheet Information - Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Balance Sheet Related Disclosures [Abstract]
Compensation related accruals	$ 3,570	$ 4,029
Accrued clinical trial expense	908	870
Other expenses	2,189	2,766
Total accrued liabilities	$ 6,667	$ 7,665

Debt - Summary of Long-term Not

Debt - Summary of Long-term Notes Payable (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021	Mar. 19, 2021
Debt Instrument [Line Items]
Unamortized debt discount and issuance costs	$ (2,950)	$ (63)
Notes payable, total	20,367	10,012
Less: current maturities	11,771	19
Long-term notes payable	8,596	9,993
Promissory Note One
Debt Instrument [Line Items]
Notes/Loan payable	16,164
2021 Term Loan
Debt Instrument [Line Items]
Notes/Loan payable	7,000	10,000	$ 30,000
Other
Debt Instrument [Line Items]
Notes/Loan payable	$ 153	$ 75

Debt - Additional Information (

Debt - Additional Information (Details) - USD ($)

1 Months Ended

2 Months Ended

3 Months Ended

6 Months Ended

10 Months Ended

Apr. 01, 2023

May 09, 2022

Dec. 31, 2021

Mar. 19, 2021

Feb. 28, 2023

Apr. 30, 2022

Jun. 30, 2022

Jun. 30, 2022

Jun. 30, 2021

Jun. 30, 2022

Jun. 30, 2021

Jan. 31, 2023

Aug. 31, 2021

Debt Instrument [Line Items]

Cash and cash equivalents

$ 32,712,000

$ 23,586,000

$ 23,586,000

$ 23,586,000

Common stock, par value

$ 0.001

$ 0.001

$ 0.001

$ 0.001

Description of securities purchase agreement

(i) purchased a secured promissory note (Promissory Note One) in the aggregate principal amount totaling $16.0 million in exchange for $15.0 million less certain expenses and (ii) agreed to purchase another secured promissory note at the Company’s election (Promissory Note Two and, together with Promissory Note One, the Promissory Notes), subject to certain conditions precedent in aggregate principal amount totaling $10.3 million in exchange for $10.0 million in cash proceeds.

Maximum purchase percentage of investors on future equity and debt securities offerings

$ 30,000

Number of shares reserved for issuance

195,426

195,426

195,426

338,106

Promissory notes interest rate

6%

Promissory note, maturity term

24 months

Promissory notes early prepayment premium percentage

10%

Promissory note, redemption description

The Redemption Conversion Price shall equal 85% multiplied by the lowest daily VWAP during the ten trading days immediately preceding the date the Lender delivers notice electing to redeem a portion of the Promissory Note. The Company’s right to satisfy the redemption amount in shares of Common Stock is subject to certain limitations, including (i) there not being any Equity Conditions Failure (as defined in the Note), (ii) the Lender and its affiliates together not owning more than 9.99% of the outstanding shares of Common Stock, and (iii) the aggregate shares of Common Stock issued upon redemption of the Promissory Notes not exceeding 19.99% of the outstanding Common Stock unless the Company has obtained stockholder approval under NASDAQ rules for such issuance.

OID and debt issuance costs

$ 63,000

$ 2,950,000

$ 2,950,000

$ 2,950,000

Interest expense

100,000

1,346,000

$ 815,000

2,483,000

$ 1,466,000

Accrued interest

100,000

100,000

100,000

Loss on debt extinguishment

$ (18,000)

(2,952,000)

(2,952,000)

$ (728,000)

2021 Term Loan Partial Repayment in April 2022

Debt Instrument [Line Items]

Repayments of debt

3,000,000

Principal Repayment

Debt Instrument [Line Items]

Repayments of debt

2,000,000

Securities Purchase Agreement

Debt Instrument [Line Items]

Number of shares reserved for issuance

37,000,000

Integrated Diagnostics Asset Purchase Agreement

Debt Instrument [Line Items]

Milestone payment

2,000,000

Promissory Note One

Debt Instrument [Line Items]

Notes/Loan payable

16,164,000

16,164,000

$ 16,164,000

Promissory Note One | Securities Purchase Agreement

Debt Instrument [Line Items]

Debt instrument, aggregate principal amount

$ 16,000,000

Proceeds from Notes Payable

15,000,000

Proceeds from net of debt issuance costs and original issue discounts

12,800,000

Description on debt instrument conditions

(i) within nine months following the First Closing Date, repayment in full all outstanding obligations under the 2021 Term Loan, (ii) the Company shall have received no less than $5.6 million in proceeds from the sale (not attributable to Lender or its affiliates) of newly issued equity securities during the period beginning on the First Closing Date and ending on January 31, 2023 (the Second Closing Date), (iii) on or before the Second Closing Date, the Company shall have met or exceeded Revenue Milestone 1 (as defined in the Promissory Notes), (iv) (a) the aggregate market value of the Company’s common stock and any other equity securities held by persons that are not affiliates of the Company on the Second Closing Date shall be greater than or equal to $75.0 million or (b) received no less than $20.0 million in additional proceeds from the sale (not attributable to Lender or its affiliates) of new equity securities in the Company not counting those proceeds set forth in item (ii) above (for total proceeds of no less than $25.6 million during the period beginning on the First Closing Date and ending on the Second Closing Date; (v) as of the Second Closing Date, Company is in good standing with Nasdaq Stock Market (the NASDAQ) and has not received any notice of non-compliance; (vi) Company shall be current in its payments to Indi, and (vii) there being no Trigger Event (as defined in the Promissory Notes) under Promissory Note One. If Promissory Note Two is issued, the terms of Promissory Note One and Note Two will be substantively identical.

Original issue discounts on debt instrument issuance

1,000,000

OID and debt issuance costs

3,200,000

Amortization of OID and debt issuance costs

300,000

Promissory Note Two | Securities Purchase Agreement

Debt Instrument [Line Items]

Debt instrument, aggregate principal amount

10,300,000

Proceeds from Notes Payable

10,000,000

Additional proceeds from issuance or sale of equity

20,000,000

Original issue discounts on debt instrument issuance

300,000

Increase in original issue discounts on debt instrument issuance, subject to contingencies

$ 500,000

Maximum

Debt Instrument [Line Items]

Promissory notes interest rate

15%

Scenario Forecast

Debt Instrument [Line Items]

Minimum liquidity balance required

$ 3,000,000

Scenario Forecast | Promissory Note One

Debt Instrument [Line Items]

Promissory Note, up on redemption

$ 1,400,000

Scenario Forecast | Promissory Note Two

Debt Instrument [Line Items]

Promissory Note, up on redemption

$ 1,000,000

Scenario Forecast | Promissory Notes

Debt Instrument [Line Items]

Rate of exit fee on redemption amount

6%

Scenario Forecast | Minimum | Securities Purchase Agreement

Debt Instrument [Line Items]

Gross proceeds from sale of common shares

$ 5,600,000

Aggregate market value of common stock and any other equity securities held by persons

75,000,000

Proceeds from issuance or sale of equity net

$ 25,600,000

2021 Term Loan

Debt Instrument [Line Items]

Notes/Loan payable

10,000,000

$ 30,000,000

7,000,000

7,000,000

$ 7,000,000

Debt instrument frequency of periodic payment

monthly

Revenue milestone

$ 65,000,000

Debt instrument description

The 2021 Term Loan provides for an “interest-only” period from the Effective Date through February 28, 2023, with interest due and payable monthly on the first calendar day of each month. However, the Company achieved a revenue milestone of at least $65 million on a trailing twelve-month basis during the three months ended March 31, 2021 which automatically extended the interest-only period through February 28, 2024. Beginning on the first calendar day of the month following the end of the interest-only period, the 2021 Term Loan shall be payable in (i) consecutive equal installments of principal through March 1, 2026, plus (ii) monthly payments of accrued interest. The principal amount outstanding under the 2021 Term Loan shall accrue interest at a floating per annum rate equal to the greater of (i) 2.00% above the prime rate, or (ii) 5.25%, which interest, in each case, shall be payable monthly. Changes to the interest rate applicable to the 2021 Term Loan based on changes to the prime rate shall be effective on the effective date of any change to the prime rate.

Repayments of debt

$ 2,700,000

Debt instrument, covenant description

The 2021 Term Loan requires the Company to comply with a minimum liquidity ratio covenant (as defined) by the 2021 Term Loan of not less than 0.95 to 1.00, and had a trailing six month rolling minimum revenue requirement of not less than 70% of the Company’s projected revenue performed at the end of each reporting period.

2021 Term Loan | Prior to First Anniversary

Debt Instrument [Line Items]

Debt instrument, prepayment penalty

3%

2021 Term Loan | Prior to Second Anniversary

Debt Instrument [Line Items]

Debt instrument, prepayment penalty

2%

2021 Term Loan | After Second Anniversary, Prior to October 19, 2025

Debt Instrument [Line Items]

Debt instrument, prepayment penalty

1%

2021 Term Loan | Thereafter

Debt Instrument [Line Items]

Debt instrument, prepayment penalty

0%

2021 Term Loan | Maximum

Debt Instrument [Line Items]

Minimum liquidity ratio covenant

0.95

Percentage of minimum revenue requirement

70%

75%

2021 Term Loan Amendment

Debt Instrument [Line Items]

Restricted cash collateral account

15,000,000

15,000,000

$ 15,000,000

2021 Term Loan Amendment | Maximum

Debt Instrument [Line Items]

Cash and cash equivalents

$ 40,000,000

$ 40,000,000

40,000,000

Second Amendment

Debt Instrument [Line Items]

Repayments of debt

20,000,000

20,000,000

Milestone payment

4,600,000

Prepayment fee waived amount

$ 600,000

Partial repayments of debt

$ 20,000,000

Third Amendment to 2021 Term Loan

Debt Instrument [Line Items]

Repayments of debt

3,000,000

Third Amendment to 2021 Term Loan | To be paid on September 30, 2022

Debt Instrument [Line Items]

Repayments of debt

$ 2,000,000

Debt - Scheduled Principal Repa

Debt - Scheduled Principal Repayments (Maturities) of Long-term Obligations (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Maturities of Long-term Debt [Abstract]
Remainder of 2022	$ 7,023
2023	14,616
2024	1,647
2025	25
2026	6
Long-term debt	$ 23,317

Leases - Additional Information

Leases - Additional Information (Details)		1 Months Ended		3 Months Ended		6 Months Ended
	Mar. 11, 2022 USD ($) ft² RenewalOption	Mar. 31, 2024 USD ($)	Jan. 31, 2022	Jun. 30, 2022 USD ($) ft²	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) ft²	Jun. 30, 2021 USD ($)	Mar. 31, 2022 USD ($)	Jan. 01, 2022 USD ($)
Lessee, Lease, Description [Line Items]
Operating lease right-of-use assets				$ 3,952,000		$ 3,952,000			$ 1,300,000
Operating lease liability				4,217,000		4,217,000			$ 1,300,000
Operating lease expense				$ 500,000	$ 300,000	$ 800,000	$ 600,000
Operating leases, Weighted-average remaining lease term (in years)				7 years		7 years
Operating leases, Weighted-average discount rate				11.40%		11.40%
Scenario Forecast
Lessee, Lease, Description [Line Items]
Accretion of lease liability		$ 25,700,000
Centennial Valley Properties I, LLC Lease Agreement
Lessee, Lease, Description [Line Items]
Operating lease right-of-use assets				$ 2,000,000		$ 2,000,000
Operating lease liability				$ 2,000,000		$ 2,000,000
Lease description						The initial term of the Lease is twelve years (the Initial Term) from the commencement date, which is the earlier of: (i) the Company conducting revenue generating business (as defined in the Lease), or (ii) April 1, 2023 (the Commencement Date), unless earlier terminated in accordance with the Lease. The Company has two renewal options to extend the term of the Lease for an additional seven or ten year terms for each renewal. During the three months ended June 30, 2022, the lease commenced for accounting purposes resulting in $2.0 million in ROU assets and lease liabilities being recorded.
Lease term	12 years
Lease commencement date	Apr. 01, 2023
Lease agreement number of options to extend | RenewalOption	2
Lease option to extend	true
Leased property building capacity | ft²	79,980
Base rent per month from commencement date	$ 227,000
Rent after fixed escalation provisions	$ 326,000
Area of leased premised obligated to pay base rent | ft²	19,980
Landlord contribution towards cost of construction and tenant improvements	$ 18,800,000
Additional Tenant improvement allowance						$ 2,000,000
Interest rate on extra allowance amount	6%
Centennial Valley Properties I, LLC Lease Agreement | Letter of Credit
Lessee, Lease, Description [Line Items]
Long-term Line of Credit	$ 5,000,000
Centennial Valley Properties I, LLC Lease Agreement | Letter of Credit | Cash Collateralized
Lessee, Lease, Description [Line Items]
Long-term Line of Credit	$ 5,000,000
Minimum
Lessee, Lease, Description [Line Items]
Operating lease, expiration term				1 year		1 year
Minimum | Centennial Valley Properties I, LLC Lease Agreement
Lessee, Lease, Description [Line Items]
Lease renewal term	7 years
Maximum
Lessee, Lease, Description [Line Items]
Operating lease, expiration term				4 years		4 years
Maximum | Centennial Valley Properties I, LLC Lease Agreement
Lessee, Lease, Description [Line Items]
Lease renewal term	10 years
COLORADO
Lessee, Lease, Description [Line Items]
Area of office space leased | ft²				29,722		29,722
Lease expiration date			2024-01			2023-01
Operating lease right-of-use assets								$ 1,200,000
Operating lease liability								$ 1,200,000
KANSAS
Lessee, Lease, Description [Line Items]
Area of office space leased | ft²				9,066		9,066
Lease expiration date						2023-10

Leases - Summary of Future Mini

Leases - Summary of Future Minimum Lease Payments for Operating Leases (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jan. 01, 2022
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
Operating leases, Remainder of 2022	$ (9,732)
Operating leases, 2023	(8,121)
Operating leases, 2024	2,619
Operating leases, 2025	3,710
Operating leases, 2026	3,979
Operating leases, 2027 and thereafter	36,327
Operating leases, Total future minimum lease payments	28,782
Operating leases, Less amount representing interest	(24,565)
Operating lease liability	$ 4,217	$ 1,300

Leases - Summary of Future Mi_2

Leases - Summary of Future Minimum Lease Payments for Operating Leases (Parenthetical) (Details) $ in Millions	Jun. 30, 2022 USD ($)
Leases [Abstract]
Tenant improvement allowances expected to be received	$ 20.8

Leases - Summary of Future Mi_3

Leases - Summary of Future Minimum Lease Payments Which Do Not Include Amounts for Common Area Maintenance, Insurance, Or Taxes, for Operating Lease Obligations (Details) $ in Thousands	Dec. 31, 2021 USD ($)
Leases [Abstract]
2022	$ 775
2023	149
2024	9
2025	3
2026	1
2027 and thereafter	0
Total	$ 937

Equity - Additional Information

Equity - Additional Information (Details)				1 Months Ended	3 Months Ended		6 Months Ended
	Apr. 08, 2022 USD ($) $ / shares	Apr. 07, 2022 shares	Mar. 07, 2022 USD ($) shares	Nov. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) $ / shares shares	Mar. 31, 2022 USD ($)	Jun. 30, 2022 USD ($) Facility $ / shares shares
Class of Stock [Line Items]
Proceeds from the sale of common shares							$ 16,135,000
Aggregate offering price					$ 14,329,000	$ 1,417,000
Subscription agreements description							On April 7, 2022, the Company entered into subscription agreements (the Subscription Agreements) with a consortium of investors (the Investors), including three members of our Board of Directors and other existing shareholders of the Company, for the issuance and sale by the Company of 6,508,376 shares of the Company’s common stock (the Shares) in an offering (the Private Placement). The three members of our Board of Directors acquired an aggregate of 3,631,284 shares pursuant to the form of a Subscription Agreement that did not include any registration rights. The remaining 2,877,092 shares were acquired by others pursuant to the form of a Subscription Agreement whereby the Company agreed to file, subject to certain exceptions, a shelf registration statement with respect to resales of such shares with the Securities and Exchange Commission no later than 60 days from April 7, 2022, which the Company filed on June 6, 2022.Pursuant to the Subscription Agreements, the Investors purchased shares at a purchase price (determined in accordance with Nasdaq rules relating to the “Minimum Value” of the Company’s common stock) of $1.79 per share, which is equal to the closing price of the Company's common stock on April 7, 2022, for an aggregate purchase price of approximately $11.7 million. The Subscription Agreements include customary representations, warranties and covenants by the parties to the agreement.WarrantsDuring 2018, the Company issued warrants to purchase shares of convertible preferred stock in conjunction with the sale of certain convertible preferred shares and issuance of debt. The Company issued to the lender a warrant to purchase 613,333 shares of Series G convertible preferred stock, at an exercise price of $0.75 per share, subject to adjustment upon specified dilutive issuances. The warrant was immediately exercisable upon issuance and expires on February 23, 2028. Through the effective date of the Company’s initial public offering (IPO) in October 2020, the Series G warrants were remeasured to an estimate of fair value using a Black-Scholes pricing model. As a result of the Company’s IPO, the preferred stock warrants were automatically converted to warrants to purchase 103,326 shares of common stock with a weighted average exercise price of $4.46 and were also transferred to additional paid-in capital. All common stock warrants remain outstanding as of June 30, 2022.
Warrants, expires period					Feb. 23, 2028		Feb. 23, 2028
Series G Preferred Stock | 2018 Notes
Class of Stock [Line Items]
Warrant issued to purchase shares | shares					613,333		613,333
Warrant, exercise price | $ / shares					$ 0.75		$ 0.75
Maximum
Class of Stock [Line Items]
Aggregate offering price				$ 50,000,000
Equity Financing Programs
Class of Stock [Line Items]
Number of facility | Facility							2
Proceeds from the sale of common shares					$ 2,900,000		$ 4,500,000
Shares of common stock issued and sold | shares					1,419,139		2,127,891
Weighted Average Price Per Share | $ / shares					$ 2.03		$ 2.11
Equity Financing Programs | Lincoln Park
Class of Stock [Line Items]
Common stock issuable, committed to purchase			$ 600,000
Purchase agreement term			36 months
Stock issuable per day, number of shares | shares			50,000
Shares issued or issuable, threshold limit description			Under applicable rules of the Nasdaq Capital Market, in no event may the Company issue or sell to Lincoln Park under the Purchase Agreement more than 19.99% of the shares of the Company’s common stock outstanding immediately prior to the execution of the Purchase Agreement (the Exchange Cap), unless (i) the Company obtains stockholder approval to issue shares of common stock in excess of the Exchange Cap or (ii) the average price of all applicable sales of common stock to Lincoln Park under the Purchase Agreement equals or exceeds $2.20 per share, such that issuances and sales of the common stock to Lincoln Park under the Purchase Agreement would be exempt from the Exchange Cap limitation under applicable Nasdaq rules.
Maximum percentage of common stock allowed to purchase by counterparty			9.99%
Shares issued as commitment fee | shares			184,275
Commitment shares issuable on conditional basis | shares			61,425
Diligence expenses and legal fees as deferred offering costs			$ 129,000
Adjustments to additional paid-in capital deferred offering costs			18,000
Deferred offering costs					$ 711,000		$ 711,000
Equity Financing Programs | Lincoln Park | Maximum
Class of Stock [Line Items]
Common stock issuable, committed to purchase			$ 50,000,000
Stock issuable per day, number of shares | shares			100,000
Stock issuable per day, value			$ 1,500,000
Shares issued as commitment fee, value			$ 20,000,000
At-The-Market Offering
Class of Stock [Line Items]
Net proceeds from sale of common shares after deducting underwriting discounts and commissions and offering expenses					$ 2,800,000		$ 4,000,000
IPO
Class of Stock [Line Items]
Warrant issued to purchase shares | shares					103,326		103,326
Warrant, exercise price | $ / shares					$ 4.46		$ 4.46
Subscription Agreements
Class of Stock [Line Items]
Price per share | $ / shares	$ 1.79
Aggregate purchase price	$ 11,700,000
Subscription Agreements | Private Placement
Class of Stock [Line Items]
Shares of common stock issued and sold | shares		6,508,376
Subscription Agreements | Private Placement | Board of Directors
Class of Stock [Line Items]
Shares of common stock issued and sold | shares		3,631,284
Subscription Agreements | Private Placement | Existing Shareholders
Class of Stock [Line Items]
Shares of common stock issued and sold | shares		2,877,092
At-The-Market Facility | Equity Financing Programs
Class of Stock [Line Items]
Remaining available capacity for share issuance					$ 29,900,000		$ 29,900,000
LPC Facility | Equity Financing Programs
Class of Stock [Line Items]
Remaining available capacity for share issuance					$ 49,200,000		$ 49,200,000

Revenue and Accounts Receivab_2

Revenue and Accounts Receivable Credit Concentration - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Disaggregation Of Revenue [Line Items]
Primary sources of revenue, description			We derive our revenue from two primary sources: (i) providing diagnostic testing in the clinical setting (Diagnostic tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, clinical trial testing, development and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics (Services).
Revenue recognized			$ 800,000
Deferred revenue	$ 2,230,000		2,230,000		$ 1,850,000
Non-current deferred revenue	$ 800,000		$ 800,000
Revenue | Minimum | Customer Concentration Risk | Medicare
Disaggregation Of Revenue [Line Items]
Concentration risk, percentage	28%	56%	33%	56%
Up Front Cash Payments
Disaggregation Of Revenue [Line Items]
Deferred revenue	$ 300,000		$ 300,000
Other Long-term Liabilities
Disaggregation Of Revenue [Line Items]
Non-current deferred revenue	$ 0		$ 0		$ 800,000

Revenue and Accounts Receivab_3

Revenue and Accounts Receivable Credit Concentration - Summary of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disaggregation Of Revenue [Line Items]
Revenues	$ 10,950	$ 11,885	$ 17,498	$ 40,751
Diagnostic Tests
Disaggregation Of Revenue [Line Items]
Revenues	10,206	10,838	15,839	38,033
Services
Disaggregation Of Revenue [Line Items]
Revenues	$ 744	$ 1,047	$ 1,659	$ 2,718

Revenue and Accounts Receivab_4

Revenue and Accounts Receivable Credit Concentration - Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers (Details) - Customer Concentration Risk - Minimum	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Revenue | The State of Colorado
Concentration Risk [Line Items]
Concentration risk, percentage	22%		16%
Revenue | The Big Ten Conference
Concentration Risk [Line Items]
Concentration risk, percentage		40%		53%
Revenue | Medicare
Concentration Risk [Line Items]
Concentration risk, percentage	28%	56%	33%	56%
Accounts Receivable | The State of Colorado
Concentration Risk [Line Items]
Concentration risk, percentage			27%
Accounts Receivable | Medicare
Concentration Risk [Line Items]
Concentration risk, percentage			26%		30%
Accounts Receivable | Janssen Research and Development, LLC
Concentration Risk [Line Items]
Concentration risk, percentage			11%		14%
Accounts Receivable | LabCorp DD (formerly Covance)
Concentration Risk [Line Items]
Concentration risk, percentage			4%		11%

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Aug. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock remained available for future issuance	29,740		29,740
Stock compensation expense	$ 1,368	$ 539	$ 2,714	$ 2,291
Number of shares reserved for issuance	195,426		195,426		338,106
Shares issued			142,680
Description of offering period under plan			ESPP provides for successive six-month offering periods beginning on September 1st and March 1st of each year.
Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted average grant date fair value	$ 2.64		$ 2.64
Options and Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Remaining unrecognized stock based compensation expense for options and restricted stock units	$ 9,400		$ 9,400
Amortized to expense period			3 years 1 month 6 days
Bonus-To-Options Program
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock compensation expense	$ 400	$ 100	$ 700	$ 700

Share-Based Compensation - Summ

Share-Based Compensation - Summary of Pre-tax Share-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total pre-tax share-based compensation expense	$ 1,368	$ 539	$ 2,714	$ 2,291
Direct Costs and Expenses
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total pre-tax share-based compensation expense	13	18	28	18
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total pre-tax share-based compensation expense	192	86	280	354
Sales, Marketing, General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total pre-tax share-based compensation expense	$ 1,163	$ 435	$ 2,406	$ 1,919

Share-Based Compensation - Su_2

Share-Based Compensation - Summary of Stock Option Activity (Details) $ / shares in Units, shares in Thousands, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Options, Outstanding - January 1, 2022 | shares	2,878
Stock Options, Granted | shares	277
Stock Options, Forfeited/canceled | shares	(154)
Stock Options, Exercised | shares	(130)
Stock Options, Outstanding - June 30, 2022 | shares	2,871	2,878
Stock Options Exercisable - June 30, 2022 | shares	1,668
Weighted Average Exercise Price, Outstanding - January 1, 2022 | $ / shares	$ 8.08
Weighted Average Exercise Price, Granted | $ / shares	3.37
Weighted Average Exercise Price, Forfeited/canceled | $ / shares	8.89
Weighted Average Exercise Price, Exercised | $ / shares	0.70
Weighted Average Exercise Price, Outstanding - June 30, 2022 | $ / shares	7.92	$ 8.08
Weighted Average Exercise Price, Exercisable - June 30, 2022 | $ / shares	$ 6.11
Weighted Average Contractual Life (Years), Outstanding - January 1, 2022	7 years 6 months	7 years 8 months 12 days
Weighted Average Contractual Life (Years), Exercisable - March 31, 2022	6 years 9 months 18 days
Aggregate Intrinsic Value, Outstanding - January 1, 2022 | $	$ 6,288
Aggregate Intrinsic Value, Outstanding - June 30, 2022 | $	1,094	$ 6,288
Aggregate Intrinsic Value, Exercisable - June 30, 2022 | $	$ 782
Bonus-To-Options Program
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Options, Outstanding - January 1, 2022 | shares	373
Stock Options, Granted | shares	244
Stock Options, Forfeited/canceled | shares	(14)
Stock Options, Outstanding - June 30, 2022 | shares	603	373
Stock Options Exercisable - June 30, 2022 | shares	603
Weighted Average Exercise Price, Outstanding - January 1, 2022 | $ / shares	$ 17
Weighted Average Exercise Price, Granted | $ / shares	2.29
Weighted Average Exercise Price, Forfeited/canceled | $ / shares	20.89
Weighted Average Exercise Price, Outstanding - June 30, 2022 | $ / shares	10.96	$ 17
Weighted Average Exercise Price, Exercisable - June 30, 2022 | $ / shares	$ 10.96
Weighted Average Contractual Life (Years), Outstanding - January 1, 2022	8 years 3 months 18 days	7 years 6 months
Weighted Average Contractual Life (Years), Exercisable - March 31, 2022	8 years 3 months 18 days
Aggregate Intrinsic Value, Outstanding - January 1, 2022 | $	$ 76
Aggregate Intrinsic Value, Outstanding - June 30, 2022 | $		$ 76

Share-Based Compensation - Su_3

Share-Based Compensation - Summary of Restricted Stock Units Activity (Details) - $ / shares	3 Months Ended	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Released	(138,000)
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding - January 1, 2022		151,000
Number of Shares, Granted		1,473,000
Number of Shares, Forfeited/canceled		(11,000)
Number of Shares, Released		(138,000)
Number of Shares, Outstanding - June 30, 2022	1,475,000	1,475,000
Weighted Average Grant Date Fair Value Per Share, January 1, 2022		$ 5.30
Weighted Average Grant Date Fair Value Per Share, Granted		2.75
Weighted Average Grant Date Fair Value Per Share, Forefeited/canceled		3.69
Weighted Average Grant Date Fair Value Per Share, Released		6.59
Weighted Average Grant Date Fair Value Per Share, June 30, 2022	$ 2.64	$ 2.64

Net Loss per Common Share - Add

Net Loss per Common Share - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2018
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Weighted-average shares outstanding used in computing net loss per share, basic and diluted	39,239,000	27,730,000	35,177,000	27,020,000
Integrated Diagnostics, Inc
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Business acquisition contingent consideration gross margin target		$ 2			$ 2
Business acquisition description			requires additional consideration to be paid by the Company to such shareholders upon attainment of a three-consecutive month
Business acquisition contingent consideration gross margin target period					7 years
Integrated Diagnostics, Inc | Common Stock
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Business acquisition description			If Indi elected to not exercise its option, the Company had 12 months to repurchase the common stock in two equal and consecutive quarterly cash installments totaling $37.0 million.
Contingent consideration shares					2,520,108
Weighted-average shares outstanding used in computing net loss per share, basic and diluted		2,520,108		2,520,108

Net Loss per Common Share - Sch

Net Loss per Common Share - Schedule of Computation of Basic and Diluted Loss per Share Attributable to Stockholders (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
Numerator
Net loss attributable to common stockholders	$ (15,824)	$ (15,586)	$ (11,402)	$ (6,961)	$ (31,410)	$ (18,363)
Denominator
Weighted-average shares outstanding, basic and diluted	39,239		27,730		35,177	27,020
Net loss per share, basic and diluted	$ (0.40)		$ (0.41)	$ (0.41)	$ (0.89)	$ (0.68)

Net Loss per Common Share - S_2

Net Loss per Common Share - Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	5,096	3,096	5,096	3,096
Options to Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	3,474	2,874	3,474	2,874
Shares Committed Under ESPP
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	44		44
Warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	103	103	103	103
Restricted Stock Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	1,475	119	1,475	119

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Provision for income taxes			$ 0
Cash paid for income taxes	$ 0	$ 0	$ 0	$ 0

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($)				1 Months Ended		3 Months Ended		6 Months Ended
	May 13, 2021	May 01, 2021	Dec. 02, 2020	Sep. 30, 2020	Aug. 31, 2019	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Oct. 31, 2016
Loss Contingencies [Line Items]
Research and development						$ 3,361,000	$ 3,323,000	$ 6,567,000	$ 6,644,000
Revenue Share Agreement | Oncimmune Limited
Loss Contingencies [Line Items]
Royalty expense						200,000	100,000	$ 400,000	300,000
Percentage of revenue share payment related to acquired diagnostic test recognized revenue for non-screening tests								8%
Minimum annual volume percentage thereafter								5%
Period of escalations of sales								through the first four years of sales
Bio-Rad License
Loss Contingencies [Line Items]
Percentage of royalty payments on net revenue					2.50%
Percentage of royalty payments not required on net revenue		2.50%
License expiry date					2024-08
Royalty expense						0	0	$ 0	0
CellCarta License
Loss Contingencies [Line Items]
Percentage of royalty payments on net revenue	0.675%
Percentage of fee payments on net sales	1%
Term of royalty payments from first commercial sale	15 years
Year of ending royalty payments from first commercial sale	2034
AVEO Oncology
Loss Contingencies [Line Items]
Remaining estimated obligation								100,000
Research and development						$ 0	$ 0	$ 0	$ 0
AVEO Oncology | Ficlatuzumab
Loss Contingencies [Line Items]
Percentage of development and regulatory costs exercised using opt-out right				50%
Percentage of royalty payments on net sales			10%
Percentage of license income generated from licensing			25%
AVEO Oncology | NSCLC POC Trial
Loss Contingencies [Line Items]
Responsible percentage of development and regulatory costs										50%